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ABSTRACT 
Psoriasis is a chronic inflammatory skin disease. Based on family studies, a strong 
genetic component exists in the etiology of psoriasis, but environmental factors are 
also needed to trigger the disease onset. Both linkage and association analyses have 
assigned the major locus for psoriasis susceptibility, PSORS1, to 6p21.3 in all 
populations studied. The PSORS1 locus has been narrowed down to an approximately 
200 kb region in the centromeric part of the MHC class I region. 
 
In this study, a novel candidate gene at the PSORS1 locus, HCR (Pg8), was cloned 
and found to be highly polymorphic. In a large trio family material from seven 
different populations, a specific allele of the HCR gene, HCR*WWCC, was shown to 
be strongly associated with chronic plaque psoriasis (PV). However, two previously 
identified susceptibility alleles of the locus, HLA-Cw*6 and CDSN*5, showed a 
similar association. These three susceptibility alleles were found to belong to the same 
extended susceptibility haplotype and their separation was not possible even with a 
sample size of almost 1700 chromosomes.  
 
The three PSORS1 susceptibility alleles were also studied in two clinical variants of 
psoriasis, guttate psoriasis (GP) and palmoplantar pustulosis (PPP), to see whether the 
locus was involved in the pathogenesis of subtypes and whether these could be used 
to differentiate the three alleles. GP was shown to have a similar but even stronger 
association with PSORS1 susceptibility alleles than PV, however, it did not help in 
separating the three genes. PPP was not associated with any of the PSORS1 alleles, 
suggesting a different etiology or molecular mechanism than for PV or GP. 
 
Functional evidence for HCR as a potential psoriasis gene was also gained. 
Expression of the HCR mRNA and protein was altered in the keratinocytes of lesional 
psoriatic skin compared with non-lesional psoriatic and normal skin. In addition, the 
HCR*WWCC allele was predicted to adopt an altered secondary structure compared 
with the wild-type allele, which could affect the antigenic properties of the protein. 
 
The PSORS1 locus is estimated to account for 30-50% of familial psoriasis, thus other 
susceptibility loci likely exist. In genome-wide linkage analyses, several minor 
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putative psoriasis susceptibility loci have been identified (PSORS2-7), but similar to 
other complex diseases, most of them have not been replicated in subsequent studies 
in different populations. In this study, a genome-wide scan in Finnish psoriasis 
families not associated with PSORS1 was performed to find other susceptibility loci. 
A minor susceptibility locus for psoriasis was mapped to 18p. The 18p locus has 
previously been suggested as a susceptibility locus for psoriasis in a British 
population. Taken together, these two mapping results yield sufficient evidence to 
name 18p as a new candidate locus for psoriasis. 
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INTRODUCTION 
Psoriasis is a chronic inflammatory skin disease affecting approximately 1-3% of 
Caucasians. Clinically, psoriasis is characterized by well-defined red, scaly plaques 
typically located on the scalp, knees or elbows. The main pathological features of 
these skin lesions are keratinocyte hyperproliferation and loss of differentiation, 
inflammatory cell infiltration and vascular changes. The molecular pathogenetic 
mechanisms of psoriasis are still largely unknown. The disease is rarely fatal but has a 
potentially devastating effect on the patient’s quality of life. Current treatments are for 
the most part palliative and may cause significant side effects. 
 
Based on family and twin studies, the etiology of psoriasis has a significant genetic 
component. However, environmental factors, such as infections, drugs, stress or 
trauma to the skin, are needed to trigger disease onset in genetically susceptible 
individuals. In segregation analyses of large multigenerational families, no clear 
inheritance pattern can be seen. Psoriasis thus belongs to a group termed genetically 
complex or multifactorial diseases. 
 
Disease gene mapping in complex diseases is far more complicated than expected 
based on successful positional cloning studies in monogenic diseases. In genome-wide 
linkage analyses, several loci for different complex phenotypes have been mapped, 
but replication of results in different populations has usually been unsuccessful. 
Psoriasis is a rare example among complex diseases in that one major genetic 
susceptibility locus has clearly been detected in all genome-wide linkage analyses 
with sufficient power. The major susceptibility locus for psoriasis, PSORS1, has been 
mapped to chromosome 6p21.3, and association analyses support its important role in 
disease etiology in all populations studied. The PSORS1 locus is estimated to account 
for a maximum of 50% of familial psoriasis, thus, other susceptibility loci likely exist. 
While several minor putative psoriasis loci have been identified, most of them have 
not been replicated in subsequent studies in different populations. 
 
The PSORS1 locus has been narrowed down to an approximately 200 kb region in the 
centromeric part of the MHC class I region. When this study was initiated, 
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susceptibility alleles of two candidate genes of the region, HLA-C and 
corneodesmosin (CDSN), had been shown to be significantly associated with 
psoriasis. At the same time, the genomic sequence of the whole MHC region had 
become available to the public databases as one of the first large completely 
sequenced genomic regions. With the genomic sequence in hand, new candidate genes 
at the PSORS1 locus could be identified. 
 
The aims of this study were to investigate a novel candidate gene at the PSORS1 
locus, HCR (Pg8), as a possible candidate gene for psoriasis, and to identify minor 
susceptibility loci for psoriasis by a genome-wide scan in families not associated with 
PSORS1. 
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REVIEW OF THE LITERATURE 
 
1. Mapping of complex diseases 
In the past two decades, many genes underlying monogenic or Mendelian diseases 
have been identified using genetic linkage and positional cloning methods. However, 
detection of genetic factors behind complex diseases has been far more complicated. 
Several features of common diseases complicate susceptibility gene mapping. One 
major problem in study design is that we do not know what we are looking for as a 
disease variant. Are there a few common alleles or multiple rare alleles underlying 
common diseases? The recent advance in defining haplotype structure and extension 
of linkage disequilibrium in the human genome has, however, increased our 
knowledge of the human genome and genetic variation, and provided new tools for 
the mapping of genes associated with the complex diseases. 
1.1. Difficulties in mapping complex diseases 
One factor complicating linkage analysis in complex diseases is locus heterogeneity. 
There are numerous reports of susceptibility genes or loci that might underlie complex 
disorders, but replication of findings has proven difficult. In different populations, 
different genetic loci may explain genetic susceptibility to a disease. The difficulty in 
defining the exact phenotype may also be one reason for locus heterogeneity because 
complex diseases typically vary in severity of symptoms and age of onset. By using 
stringent clinical diagnosis criteria and dividing patients into subgroups, the problem 
may be diminished. However, locus interaction and the existence of phenocopies 
complicate the analyses. Moreover, a strong environmental component is present in 
complex diseases (Lander and Schork 1994; Risch and Merikangas 1996; Chakravarti 
1999). 
 
1.2. Allelic structure of complex diseases 
Two models have been proposed to explain the genetic basis for complex diseases. 
The common disease-common variant (CD/CV) hypothesis suggests that the genetic 
risk for complex diseases is due to disease-predisposing alleles present at relatively 
high frequencies at a handful of loci. The opposing genetic heterogeneity hypothesis 
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proposes that numerous loci have rare alleles, each of which can cause the disease 
(Lander 1996; Cargill et al. 1999; Chakravarti 1999). Neither of the hypotheses has 
thus far been confirmed. However, based on statistical models on human population 
expansion and differences in the kinetics of rare and common alleles, the CD/CV 
model has gained more support (Pritchard 2001; Reich and Lander 2001; Pritchard 
and Cox 2002). 
 
The mutation rate is about the same for rare and common alleles. The rare alleles 
behind Mendelian disease mutations are highly penetrant and usually under very 
strong selection because of their deleterious effects on fitness. The susceptibility 
variants in complex diseases seem to have moderate to low penetrance, are less prone 
to selection and thus can reach higher frequency. The common alleles are likely to be 
of ancestral origin. For rare alleles, the allele spectrum turnover is more rapid due to 
selection and the allele frequency remains low (Pritchard 2001; Reich and Lander 
2001; Pritchard and Cox 2002). For study design, knowledge about the allelic 
structure of common diseases is crucial. Association studies are likely to be successful 
only if there are few predominating alleles. For linkage analysis, allelic heterogeneity 
does not cause a problem, but locus heterogeneity may explain unsuccessful 
replication of linkage loci in genome scans (Pritchard and Cox 2002; Smith and Lusis 
2002). 
 
Although the mapping of susceptibility genes for complex diseases has so far been 
generally disappointing, there are a few examples of successful susceptibility gene 
mapping; for example, APOEε4 allele in Alzheimer’s disease (Corder et al. 1993; 
Martin et al. 2000), PPARγ Pro12Ala (Altshuler et al. 2000) and Calpain-10 (Baier et 
al. 2000; Horikawa et al. 2000) in type II diabetes, and NOD2 (CARD15) in Crohn’s 
disease (Hugot et al. 2001; Ogura et al. 2001). Common to all of these susceptibility 
alleles is that they are fairly prevalent in the population, supporting the CD/CV 
hypothesis. Whether this is also the case in other complex diseases remains to be seen. 
These disease variants may have higher penetrance and simpler allelic architecture 
than other complex diseases (Pritchard and Cox 2002). 
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1.3. Single nucleotide polymorphisms (SNPs) 
SNPs are single base pair variations in genomic DNA for which different alleles exist 
in normal individuals and the least frequent allele has a frequency of 0.01 or greater in 
the general population. SNPs account for approximately 90% of human DNA 
polymorphism (Collins et al. 1998). In addition to bi-allelic polymorphisms, the term 
is often loosely used to describe tri- and tetra-allelic polymorphisms, sometimes also 
insertion and deletion variants. Bi-allelic SNPs comprise four different types, with the 
C/T (G/A) transition being the most common, accounting for about two-thirds of 
SNPs (Brookes 1999). Approximately three million common SNPs (minor allele 
frequency >20%) or one in every 1 kb are expected to exist in the human genome, 
which means that there is on average a 0.1% chance of any base being heterozygous 
in an individual (Taillon-Miller et al. 1998; Kruglyak and Nickerson 2001; 
Sachidanandam et al. 2001). The total number of SNPs is estimated to be as high as 
ten million (Kruglyak and Nickerson 2001). On a genome-wide level, region-specific 
differences are present in SNP density. SNPs are more frequent in non-coding than in 
coding regions, and in coding regions differences exist between genes. In the coding 
regions, synonymous SNPs, which do not cause amino acid changes, are more 
common than non-synonymous SNPs, probably due to selection against deleterious 
alleles (Cargill et al. 1999; Chakravarti 1999). 
 
The low mutation rate and essentially random nature of base-changing events make 
the SNP alleles very stable (Gray et al. 2000) and most (>80%) are common to all 
human populations, but with different allele frequencies (Sachidanandam et al. 2001). 
Because SNPs are so frequent in the genome and can be genotyped with high-
throughput methods, common SNPs are believed to be good markers for genome-
wide mapping of complex diseases. 
 
1.4. Association studies 
Association analysis is likely to be an effective tool for studying complex diseases 
because it has greater statistical power than linkage analysis when there is locus 
heterogeneity (Lander and Schork 1994; Risch and Merikangas 1996). To date, most 
association studies with complex traits have been performed as candidate-gene 
studies. The candidate genes are usually selected based on their possible biological 
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function in disease pathogenesis and directly causal variants are tested for association 
(Risch 2000; Tabor et al. 2002). Numerous positive association results have been 
published, but findings have not been replicated in subsequent studies. The reason for 
this is often poor study design (e.g. overly small study groups, inadequately matched 
controls) or that the alleles examined are not causal to the disease pathogenesis. 
Mostly non-synonymous coding SNPs have thus far been used in association analyses 
of candidate genes. However, SNPs on promoter regions or other important regulatory 
elements may also be disease-causing variants, as seen for example with the LCT 
gene variant in hypolactasia (Enattah et al. 2002). 
 
Case-control study design is the most commonly used strategy in association studies. 
The advantage of case-control study is that cases and controls are easy to obtain and 
genotype. However, the patient and control groups must be carefully selected. If the 
control group has not been adequately matched with the patient group, even 
statistically significant associations may not reflect the actual influence of the studied 
allele. Any systematic allele frequency differences between cases and controls can 
appear to be an association (Risch 2000; Cardon and Bell 2001). Isolated populations 
have been suggested as a good case-control sample set because of the homogenous 
background (Peltonen et al. 2000), even though population substructure must even 
then be considered (Kere 2001). Another way to improve control ascertainment is to 
use a prospective study cohort, which also allows monitoring of environmental 
factors. Sample size should be sufficiently large to detect significant results, and the 
findings should be replicated in another population (Cardon and Bell 2001). 
 
To reduce the effect of population stratification, family-based controls can be used 
instead of population-based controls in association analyses. The most commonly 
used family-based association test is transmission disequilibrium test, TDT (see 
Materials and Methods section 11.3.) (Spielman et al. 1993; Spielman and Ewens 
1996). Family-based tests, however, have weaker power and thus might require even 
larger sample sizes than case-control studies. In addition, as disease onset is late in 
many complex diseases, parents of the patients may be deceased (Cardon and Bell 
2001). 
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1.5. Genome-wide linkage analysis 
Genetic linkage means that alleles from two loci segregate together rather than 
independently in meiosis because of their close physical proximity on a chromosome. 
The extent of linkage between two loci is measured by the recombination fraction (θ), 
which is the fraction of meiotic events that show recombination between the loci of all 
possible meiosis. For unlinked loci θ=0.5 and for completely linked loci θ=0 (Ott 
1985; Pericak-Vance 1998). 
 
Linkage analysis is used to locate a disease gene based on its close proximity to a 
segregating marker allele on the same chromosome. Microsatellite repeats are 
commonly used as markers because they are highly polymorphic and informative, and 
densely located throughout the genome. The most powerful test for linkage is the 
LOD score method, which is a likelihood-based parametric linkage approach to 
estimate the recombination fraction and the significance of the evidence for linkage. 
The LOD score is the logarithm (log10) of the odds of linkage, which is calculated by 
dividing the likelihood of linkage at given θ by the likelihood that there is no linkage 
(θ=0.5). LOD score is commonly calculated for different θ values, and the most likely 
recombination fraction is the one that gives the highest positive LOD score (Morton 
1955; Ott 1985; Pericak-Vance 1998). 
 
Standard LOD score analysis, i.e. parametric linkage analysis, has been successfully 
used for mapping Mendelian disease genes. In parametric analysis, the inheritance 
pattern, penetrance of the trait and gene frequency must be known or correctly 
estimated. Parametric linkage analysis is very sensitive to the given parameters, and if 
they are incorrectly defined, the results can be skewed. In complex diseases, 
parametric analysis is often done using both recessive and dominant inheritance 
models with different gene frequencies and penetrance values to see which model 
gives the highest LOD score. However, when doing multiple testing, the threshold for 
a significant linkage score has to be increased accordingly. Non-parametric linkage 
analysis is the method of choice for mapping complex disease genes since prior 
knowledge of the parameters that define the mode of inheritance is not required (Xu et 
al. 1998). 
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Non-parametric linkage analysis is based on the higher than expected sharing of 
alleles by affected individuals. The predominant method used is ASP analysis, which 
monitors alleles that are IBD (identical by descent) between affected sib-pairs (Risch 
1990; Goldgar 1998). Other affected relative pairs can also be used. The NPL method 
can be used to analyze IBD allele sharing among all affected pedigree members 
simultaneously, in addition to merely monitoring affected pairs. Another advantage of 
NPL is that data for all markers on a chromosome can be evaluated simultaneously 
using a multipoint approach. However, NPL analysis is limited to pedigrees of 
moderate size since the computer time increases exponentially with the number of 
individuals (Kruglyak et al. 1996). The major disadvantage of all non-parametric 
methods is loss of power because it is often impossible to determine whether two 
alleles are IBD or IBS (identical by state). As a consequence, more families are 
needed than in parametric analyses (Pericak-Vance 1998).  
 
For simple Menedelian traits, a parametric LOD score >3 in two-point analysis has 
traditionally been used as significant evidence of linkage. This corresponds to a 5% 
significance level for a specific locus and a 9% genome-wide significance level. To 
minimize false-positive linkage results in complex diseases, more stringent criteria 
have been suggested. According to the widely accepted criteria of Lander and 
Kruglyak (1995), the linkage results are classified into the following three categories: 
suggestive evidence of linkage, significant evidence of linkage and highly significant 
evidence of linkage. These would be expected to occur one, 0.05 or 0.001 times in a 
genome scan, respectively. The corresponding LOD scores and point-wise 
significance levels in sib-pair analyses are 2.2 (P=7x10-4), 3.6 (P=2x10-5) and 5.4 
(P=3x10-7) (Lander and Kruglyak 1995). These criteria have been questioned (Morton 
1998) and only replication of a significant linkage result in a further sample can be 
interpreted as a confirmed linkage. 
 
1.6. Linkage disequilibrium mapping 
Linkage disequilibrium (LD) refers to certain alleles at two or more linked loci 
occuring together in the same chromosome more often than expected by chance. 
Because genome-wide scans and candidate gene association analyses have proven 
rather disappointing in mapping complex diseases, genome-wide LD mapping has 
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been suggested as a method of choice (Lander and Schork 1994; Kruglyak 1999; 
Reich et al. 2001; Weiss and Clark 2002). LD is disrupted by recombination, mutation 
and gene conversion events. Average LD declines with chromosomal distance, but 
there is large variation between different chromosomal regions. The biggest question 
in genome-wide LD mapping is the number of markers (SNPs) required. The first 
simulation studies estimated the average LD to be about 3 kb and suggested that up to 
500 000 SNPs would be required for successful LD mapping (Kruglyak 1999). Recent 
studies on the extent of LD in the human genome have given more promising results 
for LD mapping. LD is believed to extend on average much longer than previously 
thought (Taillon-Miller et al. 2000; Patil et al. 2001; Reich et al. 2001; Gabriel et al. 
2002). 
 
Haplotypes are now presumed to be organized into blocks, regions in which there is 
little evidence of recombination and LD is large. Within the blocks, a few common 
haplotypes account for over 80% of all haplotypes of the block (Daly et al. 2001; Patil 
et al. 2001; Gabriel et al. 2002). Considerable variance exists in the size of the blocks 
in different genomic regions (from <1kb to almost 200 kb). Studies comparing 
different populations have shown that the blocks are smaller in Nigerian Yoruban and 
African American populations than in European and Asian populations. All four 
populations share over 50% of all haplotypes, and the boundaries of the blocks are 
highly correlated across different populations. The European and Asian haplotypes are 
almost identical, and of those haplotypes present in only one population, nearly all are 
found in the Yoruban sample (Reich et al. 2001; Gabriel et al. 2002). These haplotype 
characteristics are in agreement with the ‘out of Africa’ theory. European and Asian 
populations are believed to have originated in Africa, with divergence occurring some 
100 000 years ago, resulting in a genetic bottleneck (Cavalli-Sforza 1998). 
 
For genome-wide LD mapping, the allelic structure of the blocks is promising. Over 
80% of the haplotypes of a block are defined by less than 10% of the total SNPs of the 
block. This means that as little as two or three SNPs per block, known as tag SNPs, 
are needed to identify a block. However, the haplotype map covering the whole 
genome must first be constructed, probably involving the typing of millions of SNPs 
to find the tag SNPs. When this is done, a much smaller subset of SNPs is required for 
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whole genome LD mapping (Daly et al. 2001; Johnson et al. 2001; Patil et al. 2001; 
Gabriel et al. 2002; Reich et al. 2002).  
 
1.7. Use of population isolates 
For mapping and cloning Mendelian disease genes, population isolates have proven to 
be very useful. In Finland, several rare recessive diseases have been successfully 
mapped utilizing linkage disequilibrium in positional cloning (de la Chapelle 1993; 
Peltonen et al. 1999). While expectations for using population isolates to map 
complex diseases were initially high, results have been disappointing. The studies of 
LD in population isolates of Finland and Sardinia have shown that at least in the 
regions studied LD does not extend significantly longer than in outbred populations 
(Eaves et al. 2000; Taillon-Miller et al. 2000). In these studies, however, only 
common marker polymorphisms in random non-disease chromosomes were studied. 
In the case of disease alleles, the extent of LD may differ from this background LD 
and be useful in disease mapping (Peltonen et al. 2000; Kere 2001). 
 
The population history and structure of genetic isolates, and the expected disease 
allele frequency have to be considered carefully when choosing a population isolate 
for complex disease mapping (Kruglyak 1999). In young population isolates (<100 
generations), such as Finland, Sardinia and Iceland, the allelic heterogeneity is 
reduced, but because of the fairly large number of founders, it may still be too high 
for successful mapping of a common disease variant. In these populations, extent of 
LD is only slightly elevated for common alleles, but for rare disease alleles the LD is 
likely to be longer. Very young isolates (<20 generations), such as sub-isolates in the 
Netherlands and French Canada, can provide some further advantages because they 
have experienced a very narrow bottleneck following rapid expansion. The allelic 
heterogeneity is reduced more and LD is believed to extend longer than in young 
isolates (Peltonen et al. 2000; Heutink and Oostra 2002). 
 
Population isolates also offer other advantages such as common environment and 
culture. The more uniform environmental factors may help in avoiding some of the 
environmental noise surrounding complex diseases. Some population isolates, 
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Finland, for example, have the advantage of good genealogical records and uniform 
diagnostic criteria and phenotype definitions (Peltonen et al. 2000). 
 
2. Clinical features of psoriasis 
The characteristic skin lesions in psoriasis are red, well-demarcated erythematous 
plaques of various sizes covered by grayish-white scale. The most commonly affected 
skin areas are the elbows, knees and scalp (Lomholt 1963; Roenigk 1991). Disease 
course typically waxes and wanes, and it is impossible to predict on an individual 
basis. Forty to fifty per cent of patients experience total remission of symptoms, 
lasting from a few months to decades (Lomholt 1963; Farber and Nall 1974, 1991).  
 
2.1. Clinical characteristics and related diseases 
There are several clinical subtypes of psoriasis. Chronic plaque psoriasis or psoriasis 
vulgaris (PV) is the most common, accounting for approximately 80-90% of cases 
(Lomholt 1963). The size and morphology of the plaques vary and they are usually 
symmetrically located on the extensor surfaces or scalp. Scaling is typically present. 
Guttate psoriasis (GP) is characterized by sudden onset of widely dispersed small, red, 
scaly plaques mainly over the trunk and proximal limbs. The lesions are less indurated 
and there is less scaling than in PV. GP is the presenting form at disease onset in 14-
17% of patients, but in all affected patients its prevalence is less than 10% (Lomholt 
1963; Baker 1986; Roenigk 1991). GP is seen most commonly in children or 
adolescents and is often preceded by a streptococcal throat infection (Telfer et al. 
1992; Mallon et al. 2000). In most cases, GP is self-limiting (acute GP), but a 
significant proportion of patients develop PV later in life. Guttate flares can also be 
seen in patients with chronic PV (Naldi et al. 2001). Other clinical subtypes of 
psoriasis are inverse, erythrodermic and pustular psoriasis. Typical features of the 
various types are shown in Table 1 (Farber and Nall 1991; Wright and Baker 1991a, 
b). 
Palmoplantar pustulosis (PPP) has some features in common with other forms of 
pustular psoriasis and is often classified as a localized form of pustular psoriasis 
(Baker 1986; Lever and Schaumburg-Lever 1990). However, the relationship between 
PPP and psoriasis is controversial. Up to 24% of PPP patients have psoriasis (Enfors 
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and Molin 1971), which is much higher than the normal population prevalence of 
psoriasis (see section 2.2.). PPP is characterized by painful sterile pustules on 
erythematous, scaly skin confined to palms and soles. PPP is relatively rare, with a 
prevalence of 0.01-0.05% (Lomholt 1963; Hellgren and Mobacken 1971). The age of 
onset is usually between 30 and 50 years, and women are more often affected (Enfors 
and Molin 1971; Hellgren and Mobacken 1971; Eriksson et al. 1998). PPP is strongly 
associated with tobacco smoking (Rosen et al. 1982; Akiyama et al. 1995). 
 
Table 1. Clinical characteristics of different subtypes of psoriasis. 
 
Type of psoriasis Clinical characteristics 
Plaque psoriasis - most common form 
- size and morphology of the plaques vary 
- usually located on extensor surfaces or scalp 
- scaling is typically present 
Guttate psoriasis - most common in children and adolescents 
- often preceded by streptococcal throat infection 
- skin lesions are small and usually widely located on the 
upper trunk and extremities 
Inverse psoriasis - occurs as erythema in e.g. groin and axillary regions  
- scaling is absent 
Erythrodermic psoriasis - can cover almost the entire cutaneous surface of the body 
- can be accompanied by systemic metabolic disturbances, 
e.g. hypoalbunemia 
Pustular psoriasis - sterile pustules in erythematous and scaly skin 
- localized or generalized 
 
- palmar/plantar psoriasis 
 
Nail changes are common in psoriasis patients, reported in up to 50% of patients. 
These include pitting, discoloration, subungual hyperkeratosis and onycholysis (Baker 
1986; Scher 1991). Psoriasis can also be associated with a seronegative 
spondyloarthropathy referred to as psoriatic arthritis (PsA) (Espinoza et al. 1992; 
Kaipiainen-Seppanen 1996; Hohler and Marker-Hermann 2001). Epidemiological 
studies on PsA report an estimated overall prevalence of 0.1% and a prevalence of 5-
30% in patients with psoriatic skin disease. Of patients with extensive skin 
involvement, up to 40% have PsA (Molin 1976; Espinoza et al. 1992; Braun et al. 
1998). The arthritis involved is commonly a symmetric or asymmetric oligoarthritis, 
affecting distal interphalangeal joints. It can also manifest as a severe deforming 
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arthritis that involves multiple small joints in the hands, feet and spine (Moll and 
Wright 1973; Molin 1976; Espinoza et al. 1992). 
 
Several factors are known to trigger the onset of psoriasis and to induce flares in 
disease course (Lomholt 1963; Farber and Nall 1974, 1991). These include emotional 
stress (in 23% of patients), drugs (e.g. beta-blockers, lithium) (in 16%), physical 
trauma (in 43%) known as Koebner phenomenon, infections (in 14%) and alcohol 
intake (Farber and Nall 1974; Poikolainen et al. 1990; Krueger and Duvic 1994; 
Poikolainen et al. 1999; Higgins 2000; Raychaudhuri and Gross 2000). Streptococcal 
pharyngitis has been associated with the onset of guttate psoriasis, in particular, but is 
also reported to exacerbate chronic plaque psoriasis (Telfer et al. 1992; Leung et al. 
1995; Wardrop et al. 1998; Mallon et al. 2000). 
 
2.2. Prevalence 
The prevalence of psoriasis is usually reported to be 1-3%. However, studies in 
different populations show considerable variation in the occurrence of the disease. 
The prevalence is lowest in Chinese (0.4%) and in West African (0.3-0.7%) and 
American (0.7%) black populations. In Japan and India, the prevalence is 0.3-1% and 
0.8%, respectively. In Caucasoid populations, the prevalence varies between 1 and 5% 
(Farber and Nall 1991) being, for example, 3% in Denmark (Brandrup and Green 
1981), 2.5% in Australia (Duffy et al. 1993), 2.8% in the Faroe Islands (Lomholt 
1963) and 4.8% in Norway (Kavli et al. 1985). When one considers that some people 
may have only a single lesion and never seek medical attention, the actual prevalence 
may be higher (Christophers 2001). Psoriasis is equally common in both sexes 
(Lomholt 1963; Farber and Nall 1974; Brandrup and Green 1981; Kavli et al. 1985; 
Henseler and Christophers 1995). 
 
2.3. Age of onset 
The average age of onset is 20-30 years, but the disease can erupt at any age (Watson 
et al. 1972; Farber and Nall 1974; Duffy et al. 1993). In women, the average age of 
onset is somewhat lower than in men (Farber and Nall 1974; Henseler and 
Christophers 1985). The age of onset distribution is, however, bimodal and a second 
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peak is seen around 57-60 years, without a significant difference between the sexes 
(Henseler and Christophers 1985; Smith et al. 1993). In 35% of patients, the age of 
onset is before 20 years, and in 58%, before 30 years (Farber and Nall 1991). 
Approximately 70% of psoriasis patients are affected by 40 years of age (Watson et 
al. 1972; Henseler and Christophers 1985).  
 
The clinical features of psoriasis and familial aggregation vary according to the age of 
onset. When the age of onset is early, the disease course is often unstable, with 
frequent relapses and extensive body involvement (Lomholt 1963; Farber and Nall 
1974; Henseler and Christophers 1985; Stuart et al. 2002). In addition, most patients 
who have an affected family member belong to the early-onset group (Farber et al. 
1974; Henseler and Christophers 1985; Smith et al. 1993). Based on the age of onset 
and familial occurrence, two clinical types of psoriasis can be separated. Type I 
psoriasis has an onset before the age of 40 years, is familial and its clinical picture is 
more severe. The HLA-Cw*6 allele association (see section 4.3.2.) is found mainly in 
type I patients. Type II psoriasis is sporadic, the age of onset is over 40 years and the 
disease course is often milder (Henseler and Christophers 1985; Swanbeck et al. 
1995).  
 
3. Pathogenesis of psoriasis 
The main pathogenetic features of psoriatic lesions are abnormal keratinocyte 
differentiation and hyperproliferation, infiltration of inflammatory cells and vascular 
changes. Accordingly, keratinocytes, fibroblasts and cells involved in the immune 
response (antigen-presenting and T cells) or vascular system (endothelial cells) are all 
suggested as primary defects in the disease process. Interactions between the different 
cell types via cytokines play an important role in the disease process, but the 
pathogenetic mechanisms are still largely unsolved (Baker and Fry 1992; Kadunce 
and Krueger 1995; Bhalerao and Bowcock 1998; Bos and De Rie 1999; Ortonne 
1999). 
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3.1. Keratinocytes 
In psoriatic skin, keratinocyte differentiation is abnormal, resulting in parakeratosis 
and loss of the granular layer. The keratinocytes are also hyperproliferative. These 
changes are believed to be secondary to altered growth and maturation kinetics of 
keratinocytes. In psoriatic plaques, the cell cycle of proliferating keratinocytes is eight 
times shorter and the proliferating cell population is two times greater than in control 
skin (Weinstein et al. 1985). Normally, only a small portion of the keratinocyte stem 
cells in the basal layer is active in cell cycling. In psoriatic skin, the percentage of 
stem cells participating in cell division seems to be increased (Bata-Csorgo et al. 
1993). Alternatively, the number of cell cycles in a transiently amplifying cell 
population might be increased (McKay and Leigh 1995). The factors leading to these 
changes in keratinocytes remain obscure. 
 
There is also a disturbance in keratinocyte adhesion in psoriatic skin lesions. Integrins 
are important in cell-cell interactions and in adhesive properties of keratinocytes. 
They also play a role in the initiation of terminal differentiation of keratinocytes 
(Adams and Watt 1989). The polarized topography of integrin expression and the 
integrin-cytoskeleton association are altered in non-lesional and lesional psoriatic skin 
compared with normal skin, but whether the changes are primary or secondary to 
some other stimulus is not known (Hertle et al. 1992; Pellegrini et al. 1992).  
 
3.2. Inflammatory cells 
Strong evidence indicates that inflammatory cells, especially T lymphocytes, have an 
important role in the pathogenesis of psoriasis. T lymphocytes accumulate early in the 
developing plaque and immunosuppressive drugs targeted against T lymphocytes (e.g. 
cyclosporin A) are effective in treating active psoriasis (Griffiths et al. 1986). 
Psoriasis can be exacerbated by HIV infection, which is known to infect the CD4+ T 
cells (Johnson et al. 1985; Duvic 1990). Experiments with an immunodeficient SCID 
mouse model have also supported the important role of immunomechanisms in 
pathogenesis. In one study, non-lesional skin from psoriasis patients and skin from 
healthy controls were grafted onto SCID mice. After injection of autologous 
immunocytes, psoriatic plaques developed in uninvolved skin from psoriasis patients 
but not in control skin. Histological and immunohistological staining of the plaques 
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revealed typical features of psoriatic plaques (Wrone-Smith and Nickoloff 1996). 
There are also case reports of clearance or development of psoriasis following 
allogenic bone marrow transplants (Snowden and Heaton 1997; Kanamori et al. 
2002). Whether the inflammatory response in psoriasis is primary or secondary to 
some other stimulus remains to be elucidated. 
 
3.3. Cytokines 
The expression of several cytokines is altered in psoriatic skin. Because of the 
complex interaction of the cytokines, it is unlikely that over- or underexpression of a 
single cytokine could be the sole pathogenetic mechanism. IL-6 is a major mediator of 
the host response to injury and infection. It also enhances B and T cell proliferation 
and activation of B cells, T cells and macrophages. It is present in increased amounts 
in psoriatic skin (Grossman et al. 1989; Ohta et al. 1991). IL-8 is a potent T cell and 
neutrophil chemoattractant and is also overexpressed in the psoriatic skin (Gillitzer et 
al. 1991). Both IL-6 and IL-8 are produced in part by keratinocytes and have been 
shown to stimulate keratinocyte proliferation in vitro (Grossman et al. 1989; Tuschil 
et al. 1992). TGF-α is produced by keratinocytes and has mitogenic and angiogenic 
properties. Both TGF-α mRNA and protein levels are overexpressed in psoriatic 
lesions. TGF-β, by contrast, inhibits epithelial growth and its mRNA levels in 
psoriatic skin are not significantly different from those in normal skin (Elder et al. 
1989). 
 
IFN-γ is produced by activated lymphocytes and has the ability to induce the 
expression of the adhesion molecule ICAM-1. TNF-α can also induce ICAM-1 but to 
a lesser extent. Both IFN-γ and TNF-α are believed to be important in the trafficking 
of T lymphocytes to the psoriatic epidermis (Griffiths et al. 1989; Terajima et al. 
1998). The amount of TNF-α in psoriatic lesions is elevated compared with that in 
control skin (Bonifati et al. 1994; Ettehadi et al. 1994; Terajima et al. 1998).  
 
IL-1 stimulates production of other cytokines by keratinocytes and induces vascular 
endothelial cell adhesion molecules for leukocytes (ELAM-1, VCAM-1, ICAM-1), 
which could account for the infiltration of leukocytes into psoriatic lesions. The 
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expression of ELAM-1 and ICAM-1 has been shown to be higher in psoriatic skin 
than in normal skin (Gillitzer et al. 1991). Keratinocytes themselves also produce IL-
1, which stimulates the expression of KGF and GM-CSF in fibroblasts. These 
fibroblast-derived factors in turn stimulate keratinocyte proliferation and 
differentiation via a paracrine regulation mechanism (Smola et al. 1993; Maas-
Szabowski et al. 1999; Werner and Smola 2001). 
 
3.4. Pathogenetic models 
Cytokines together with inflammatory cells and keratinocytes, which synthesize and 
secrete the cytokines after appropriate stimuli, form a complex network of signalling. 
One proposed immunopathogenetic model is shown in Figure 1 (Krueger 2002). 
 
Figure 1. (1) APCs capture antigens in the epidermis, which leads to their activation and migration to 
lymph nodes. In lymph nodes, naive T lymphocytes recognize antigens bound to class I or II MHC 
molecules on APCs. T cells are activated, acquire the skin-homing receptor CLA and differentiate into 
type 1 or 2 effector lymphocytes. (2) CLA+ memory T cells enter the circulation and exit cutaneous 
blood vessels at the site of inflammation. (3) In the dermis and epidermis, T cells become activated to 
release cytokines upon encountering the initiating antigen. In psoriasis, type I lymphocytes are 
expanded and release several cytokines, e.g. γ-interferon, which cause increased expression of 
inflammatory proteins and adhesion molecules for leukocytes on keratinocytes. (4) Intraepidermal T 
cells trigger keratinocyte hyperproliferation, but direct stimulation of keratinocytes by e.g. epidermal 
injury has also been suggested. (5,6) Cytokine-activated keratinocytes produce cytokines, chemokines 
and various other growth factors that stimulate neutophil influx, vascular alterations and keratinocyte 
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hyperplasia. (CLA, cutaneous lymphocyte-associated antigen; LFA, lymphocyte associated antigen; 
PNAd, peripheral lymph node addressin; TCR, T cell receptor; Tc1, type 1 cytotoxic T cell; Th1, type I 
helper T cell; V-EGF, vascular endothelial growth factor; KC, keratinocyte; LC, Langerhans cell; DC, 
dendritic cell; PMN, polymorphonuclear leukocyte) (Modified from Krueger 2002). 
 
No animal model is available for psoriasis. Some psoriasiform features, such as 
epidermal hyperproliferation, a mixed inflammatory infiltrate and vascular changes, 
can be seen in mice homozygous for the chronic proliferative dermatitis (cpd) and 
flaky skin (fsn) mutations (Schon 1999). However, these mice seem to lack T cell-
based immunopathogenesis, and thus their value for psoriasis research is limited. In 
the last ten years, several transgenic mouse models for psoriasis have been developed. 
Most of these overexpress some cytokine or growth factor that show altered 
expression in psoriasis under the K14 or involucrin promoter (e.g. K14/IL-1α, 
K14/IL-6, K14/TGFα, involucrin/IFNγ). Nevertheless, the transgenic mice only 
possess some of the pathogenetic features seen in psoriasis. This emphasizes the 
importance of the interaction between different cell types and cytokines in the disease 
process (Vassar et al. 1991; Turksen et al. 1992; Carroll et al. 1995; Groves et al. 
1995; Schon 1999).  
 
4. Genetics of psoriasis 
Based on family and twin studies, a strong genetic component is present in the 
pathogenesis of psoriasis, but the segregation of the disease in most pedigrees does 
not obey simple Mendelian laws. Moreover, environmental factors are needed to 
trigger disease onset in a genetically susceptible individual. Further support for the 
genetic basis of psoriasis has come from HLA association studies, and in linkage 
analyses, several susceptibility loci for psoriasis have emerged. In genome-wide 
scans, most of the patients have been diagnosed as having chronic plaque psoriasis 
according to the standard diagnostic criteria. However, subtypes of psoriasis may exist 
in the psoriasis vulgaris group, accounting for locus heterogeneity.  
 
4.1. Family and twin studies 
In family studies, a clear familial aggregation of psoriasis can be seen. In a population 
study of psoriasis in the Faroe Islands, Lomholt (1963) examined some 11 000 
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inhabitants, a third of the entire population, and reported that 91% of patients had an 
affected family member. In another large study, 36% of patients had an affected 
relative and 47% of first-degree relatives had psoriasis (Farber and Nall 1974). Other 
studies have reported a somewhat lower but consistent prevalence of psoriasis in first-
degree relatives of patients, approximately 12-19% in parents and 9-16% in siblings 
(Lomholt 1963; Watson et al. 1972; Melski and Stern 1981; Brandrup 1984; 
Swanbeck et al. 1994). In a large Swedish family data set, the estimated lifetime risk 
of psoriasis was 28% when one parent was affected and 24% when an affected sibling 
was present (Swanbeck et al. 1997). 
 
In twin studies, the concordance rates for monozygotic and dizygotic twins are 
different. The concordance in MZ twins is much higher, 63-73%, compared with the 
17-20% in DZ twins (Farber et al. 1974; Brandrup et al. 1978; Brandrup et al. 1982). 
In an Australian population, the concordance rates were lower in both groups (35% in 
MZ twins and 12% in DZ twins), but in agreement with earlier studies (Duffy et al. 
1993). The much higher concordance in MZ versus DZ twins speaks for a strong 
genetic component. In addition, such clinical features as distribution pattern of 
plaques, severity, and disease course are similar in MZ twins but not in DZ twins. 
However, because the concordance never reaches 100% in MZ twins, environmental 
factors are also needed to trigger disease onset. 
Based on twin studies, the overall heritability is estimated to be 80-91% (Brandrup et 
al. 1978; Brandrup and Green 1981; Brandrup et al. 1982; Duffy et al. 1993). Similar 
heritability estimates of 82-87% have been obtained from segregation analyses of 
population data from the Faroe Islands and Poland (Pietrzyk et al. 1982b; Iselius and 
Williams 1984). 
 
4.2. Inheritance models 
Based on family studies, several different inheritance models have been proposed to 
explain the segregation of psoriasis. An autosomal dominant inheritance model with 
incomplete penetrance was suggested in two studies, both examining one large 
pedigree (Ward and Stephens 1961; Abele et al. 1963). Moreover, an autosomal 
recessive model with a high gene frequency (25%) explained the inheritance best in a 
Swedish population study (Swanbeck et al. 1994). However, a dominant inheritance 
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model with low penetrance (<50%) was also compatible with the Swedish data. This 
was probably due to a pseudodominant inheritance pattern, i.e. segregation that 
appeared to be dominant in pedigrees, which can result from a recessive mode of 
inheritance with very common disease alleles (Swanbeck et al. 1994). 
 
In most studies, the disease segregation in families does not fit simple Mendelian 
models. When Lomholt’s family data from the Faroe Islands (Lomholt 1963; Iselius 
and Williams 1984) and family data from a Polish population (Pietrzyk et al. 1982a; 
Pietrzyk et al. 1982b) were analyzed using a mixed model of complex segregation 
analysis, some of the families showed multifactorial and others monogenic 
inheritance. Elder et al. (1994) proposed a multilocus model after reanalyzing 
Lomholt’s data (Elder et al. 1994). Watson et al. (1972) also concluded that only a 
multifactorial inheritance model could explain their material. Furthermore, in a study 
of first-degree relatives of Danish psoriatic twins, an autosomal dominant model with 
reduced penetrance or multifactorial inheritance was most probable (Brandrup 1984). 
 
Genomic imprinting has also been proposed as a genetic mechanism for psoriasis, 
with two supporting observations from population studies. The birth weight of the 
children of psoriatic fathers is higher than that of psoriatic mothers or controls 
(Traupe et al. 1992; Swanbeck et al. 1994). In addition, the offspring of a psoriatic 
father are more often affected than offspring of a psoriatic mother or gene carrier 
(Traupe et al. 1992). A model of allelic instability in mitosis has also been suggested 
as a possible inheritance mechanism because great variability is present in the age of 
onset and severity of the disease, and the magnitude of genetic anticipation is greater 
when inherited from the father (Theeuwes and Morhenn 1995). 
 
Based on all of these studies, one can conclude that in some large pedigrees 
Mendelian inheritance with lowered penetrance explains the disease segregation, but 
in most families, the mode of inheritance is more complicated. Current opinion is that 
psoriasis belongs to the complex diseases group and that the inheritance is 
multifactorial (Henseler 1998; Barker 2001; Elder 2001). 
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4.3. The HLA association 
4.3.1. The Major Histocompatibility Complex 
The MHC is an extended region of about 4 million bp on human chromosome 6, 
between 6p21.31 and 6p21.32, usually referred to as the HLA (human leukocyte 
antigen) system. It contains over 200 genes, more than 40 of which encode for 
leukocyte antigens involved in immune response. While some of the other genes in 
the region are functionally involved with the HLA genes, a large number have nothing 
to do with immunity. The HLA genes that are involved in the immune response are 
grouped into the HLA class I and II genes, which are both functionally and 
structurally different (Margulies 1999; Klein and Sato 2000a). 
 
The major (or classic) class I genes, HLA-A, HLA-B and HLA-C, are expressed by 
most somatic cells. The class II genes are grouped into the main classes of HLA-DM, 
-DO, -DP, -DQ and –DR, and further into two families, A or B, based on the chain (α 
or β). The class II genes are normally expressed only by immune cells (B cells, 
macrophages, dendritic cells, activated T cells and thymic epithelial cells), but in the 
presence of γ interferon other cell types can also express them (Margulies 1999; Klein 
and Sato 2000a). 
 
The class I and II MHC molecules are cell surface receptors that recognize and bind 
antigen fragments, and after processing, present them to the T cells, initiating an 
immune response. The peptide fragments of cytosolic proteins (worn-out or defective 
proteins of the cell or viral proteins) are presented by HLA class I molecules, and 
extracellular proteins (self or foreign) by class II molecules. The HLA-peptide 
complexes formed interact with T cell receptors or CD4-CD8 co-receptors of the T 
cells. The MHC molecules can also serve as elements for signal transduction for 
natural killer (NK) cells and either protect or activate natural killing of the target cell 
(Margulies 1999; Klein and Sato 2000a). 
 
The HLA genes exhibit a high degree of polymorphism, which allows the binding and 
presentation of a large number of different antigens. In addition to foreign pathogens, 
HLA class I molecules in particular have an important role in self-recognition by the 
immune system and are largely responsible for the acceptance or rejection of organ 
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transplants. The MHC also plays a role in the etiology of many autoimmune diseases, 
but the precise mechanism remains obscure. Certain alleles or haplotypes of HLA 
genes are significantly more common in patients compared with controls in some 
diseases; for example, HLA-B27 in ankylosing spondylitis, DR4 in rheumatoid 
arthritis, DR3 in celiac disease and DQB1*0302 in IDDM. Psoriasis is the only 
disease that is known to be associated with the HLA-C gene (Margulies 1999; Klein 
and Sato 2000b). The MHC region is composed of blocks within which recombination 
appears to be very rare and tight linkage disequilibrium exists between the alleles, 
forming extended conserved haplotypes (Marshall et al. 1993). 
 
4.3.2. The HLA association with psoriasis 
The first studies reporting an association between psoriasis and the HLA antigens 
were published already in the 1970s. They were motivated by the findings that 
streptococcal infections often preceded onset of psoriasis and that a protein from 
group A haemolytic streptococcus was shown to cross-react with certain HLA 
antigens (Tervaert and Esseveld 1970; Farber and Nall 1974). Russel et al. (1972) 
found a significant increase of the HLA-B13 (A13) and –B17 (W17) alleles in 
psoriasis patients compared with controls (27.3% and 22.7% in psoriasis patients and 
3.4% and 9% in controls, respectively) when studying 44 Caucasian patients and 89 
controls (Russell et al. 1972). The HLA-B13 (A13) and HLA-B17 (W17) alleles were 
also shown to be associated with psoriasis in subsequent studies (White et al. 1972; 
Karvonen et al. 1976; Tiilikainen et al. 1980). In a Finnish population sample, 45.9% 
of psoriasis patients were HLA-Cw*6 carriers compared with 7.4% of random blood 
donors (P<0.0001) (Tiilikainen et al. 1980). The early HLA association studies were 
done with a serological typing method that is known to be insensitive to HLA-C and 
fails to detect many HLA-C alleles completely (Bunce et al. 1996). With more 
specific DNA-based genotyping methods, the HLA-Cw*6 allele association has been 
the strongest and most consistently reported HLA association in psoriasis. In a study 
of 201 Swedish patients and 77 controls, the frequency of the HLA-Cw*6 allele in 
patients (66.7%) was significantly increased compared with controls (11.7%) 
(Enerback et al. 1997). In a case-control study of a UK population, the HLA-
Cw*0602 allele was seen in 47% of patients and 20% of controls (P<0.0001) (Mallon 
et al. 1997). 
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In two studies, a specific amino acid change, alanine instead of threonine at position 
73 of the HLA-C gene, was reported to be associated with psoriasis (Asahina et al. 
1991; Ikaheimo et al. 1994). This change is seen in the HLA-Cw*6 allele, but it is not 
unique to Cw*6. The HLA-Cw*4, -Cw*7, -Cw*12, -Cw*1503 and –Cw*17 alleles 
also have Ala 73 in their coding regions (Kostyu et al. 1997; Mallon et al. 1997). In 
the UK population, Ala 73 was present at high frequencies in both psoriasis patients 
(88.5%) and the control group (84.3%) and showed a significant association with 
psoriasis only in male patients with type I disease (Mallon et al. 1997). The authors 
concluded that the HLA-Cw*0602 allele was probably playing the major role in the 
association, not Ala 73 (Mallon et al. 1997). In a Japanese population, the HLA-Cw11 
allele was significantly more common in patients than in controls (57% vs. 9%), but 
HLA-Cw6 and –Cw7 also showed an increased risk (Nakagawa et al. 1990). 
 
In several studies, the frequency of the HLA-Cw*0602 allele has been much higher in 
psoriasis patients with early onset disease (before age 40 years) than in those with late 
onset disease (after age 40 years) (Tiilikainen et al. 1980; Henseler and Christophers 
1985; Enerback et al. 1997; Mallon et al. 1997). In addition, HLA-Cw*6 positive and 
negative patients have been reported to have different clinical features. The disease 
course is often more severe in patients with the HLA-Cw*6 allele than in HLA-Cw*6 
negative patients (Guedjonsson et al. 2002).  
 
HLA class II alleles have also been reported to be associated with psoriasis. In a 
Taiwanese population, HLA-DRB1*0701 was seen in 11% of patients and in 2% of 
controls (P=0.001) (Jee et al. 1998). In a Caucasian population, in addition to the 
HLA-Cw*6, -B*13 and –B*57 alleles, DRB1*0701, DQA1*0201 and DQB1*0303 
were over-represented in type I psoriasis patients (Schmitt-Egenolf et al. 1993; 
Ikaheimo et al. 1996). Furthermore, an extended haplotype, EH57.1, containing 
Cw*6-B*57-DRB1*0701-DQA1*0201-DQB1*0303 was significantly more common 
in type I psoriasis patients than in controls (P=0.00021). Individuals carrying class I 
alleles of EH57.1 but lacking the class II alleles were significantly more common in 
the type I psoriasis patient group (12%) than in the control group (2%) (P=0.0060). 
By contrast, possessing only the class II alleles of the haplotype and lacking the class 
I alleles was not associated with psoriasis. HLA-Cw*6 and –B*57 appear to be the 
actual markers for psoriasis susceptibility, with the class II allele association likely 
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being due to linkage disequilibrium between the alleles (Schmitt-Egenolf et al. 1996). 
Jenisch et al. (1998) also reported that the class I haplotype of EH57.1 was selectively 
retained among affected individuals and that the HLA-Cw*6 allele was the strongest 
predictor of psoriasis risk of the HLA alleles. The authors did, however, suggest that 
the HLA-Cw*6 allele itself was unlikely to be the direct determinant of susceptibility 
but rather was in tight linkage disequilibrium with it (Jenisch et al. 1998).  
 
4.4. Linkage analyses 
 
17q25 PSORS2 
The first genome-wide scan in psoriasis, performed in 1994, localized a susceptibility 
locus at 17q25 (PSORS2). Eight large Caucasian families from USA with 65 affected 
individuals were analyzed using a dominant inheritance model. A total LOD score of 
5.7 (θ=0.15) was obtained from six families, but the score came mostly from one large 
family (LOD 5.3) (Table 2) (Tomfohrde et al. 1994). However, in a study of a large 
family from Northeast England, the 17q25 linkage was excluded (Matthews et al. 
1995). A study of 24 North American multiplex families using 12 microsatellite 
markers also failed to detect linkage at 17q25, but there was suggestive evidence of 
allele sharing for three distal 17q markers (Nair et al. 1995). 
 
4q PSORS3 
In a subsequent study by Matthews et al. (1996), a large Irish family showed some 
evidence of linkage at 17q (LOD 1.24, θ= 0.0), but six other multiplex families were 
unlinked. The authors continued with a genome-wide scan in one of the unlinked 
families using a dominant model with 70% penetrance and got a positive linkage 
result at 4q. When the locus was studied with further markers in all the six families 
unlinked to 17q, a total two-point LOD score of 3.03 (θ=0.08) was obtained. Non-
parametric linkage analysis supported the linkage at 4q (PSORS3) with a NPL of 4.2 
(P=0.0026) (Matthews et al. 1996). 
 
6p21.3 PSORS1 
Trembath et al. (1997) performed a two-stage genome scan with 106 affected sib-pairs 
from 68 Caucasoid families from the UK. Using non-parametric statistics, they found, 
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for the first time, significant evidence of linkage to the MHC region on chromosome 
6p21.3 (PSORS1) (LOD 6.5, P=5.8x10-7). Regions of possible linkage were reported 
on chromosomes 2 (LOD 1.27, P=0.008), 8 (LOD 2.6, P=0.0003) and 20 (LOD 2.01, 
P=0.001) (Trembath et al. 1997). 
 
In a genome-wide scan of 86 nuclear and 29 extended families with 182 independent 
sib-pairs from USA and Germany, significant linkage was also obtained on 6p21.3 
(Zmax= 3.52, P=2.9x10-5). Both parametric linkage with several models and non-
parametric linkage were analyzed, and two novel loci at 16q (Zmax=2.50, P=0.00034) 
and 20p (Zmax=2.62, P=0.00026) under a recessive model were found. The previously 
reported 17q25 locus also showed evidence of linkage (Zmax=2.09, P=0.00097) under 
a dominant model allowing heterogeneity (Nair et al. 1997). The 16q locus was 
interesting because it overlapped a susceptibility locus for Crohn’s disease (Hugot et 
al. 1996; Rioux et al. 2000) and an increased co-occurrence of psoriasis and Crohn’s 
disease has been reported (Lee et al. 1990; Nair et al. 1997). Polymorphisms of the 
NOD2 gene at the 16q locus have been reported to be associated with Crohn’s disease 
(Hugot et al. 2001; Ogura et al. 2001). The NOD2 gene polymorphisms, however, 
showed no association with psoriasis (Nair et al. 2001; Plant et al. 2002). 
 
The 6p21.3 locus yielded evidence for linkage also in a family material collected from 
Scotland. A maximum LOD score of 4.63 was reached under a dominant inheritance 
model with 70% penetrance and 5% phenocopies. There was also evidence of excess 
allele sharing between affected siblings. The 4q and 17q loci did not show evidence of 
linkage in this cohort of 103 families (301 affected individuals) (Burden et al. 1998). 
 
1q21 PSORS4 
No evidence of linkage to 6p or 17q was seen when 22 Italian multiplex pedigrees 
were analyzed. Moreover, the other previously reported susceptibility regions on 2p, 
4q, 8q, 16q and 20p were excluded in one large family. In a genome-wide scan with 
the same family using a dominant model, a putative linkage at 1q21 was observed. All 
families taken into the analysis yielded a maximum LOD score of 3.75, θ=0.05. Non-
parametric analysis also showed evidence of linkage at the 1q21 locus (PSORS4) 
(NPL=4.07, P=0.0001) (Capon et al. 1999). The PSORS4 is interesting as a psoriasis 
candidate locus, because it coincides with the region of the Epidermal Differentiation 
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Complex. In subsequent fine mapping using linkage disequilibrium analysis in two 
independent Italian sample sets, the region has been further refined (Capon et al. 
2001). 
 
3q21 PSORS5 
In a genome-wide scan of 20 Swedish families, a suggestive linkage was found at a 
novel locus on 3q using a recessive model with 25% penetrance. In an extended 
family material with 47 families, a LOD score of 3.36 was obtained at 3q. The locus 
was further analyzed with 153 sib-pairs using non-parametric statistics, yielding a 
maximum NPL value of 1.77 (P=0.04). After stratifying all 104 families according to 
their origin, a NPL value of 2.77 (P=0.003) at 3q21 (PSORS5) was gained in families 
originating from southwest Sweden (Enlund et al. 1999). In another genome scan with 
a denser marker map and 134 sib-pairs also included in the previous study of 3q, the 
families were stratified according to joint complaints. With non-parametric linkage 
analysis, NPL score of 2.83 (P=0.002) was obtained at 6p21.3 in families without 
joint symptoms. The 3q21 locus was also linked in non-joint involvement families 
(NPL 2.89, P=0.002), and the chromosome 15 locus in families with joint complaints 
(NPL 2.96, P=0.0017) (Samuelsson et al. 1999). Recently the PSORS5 locus at 3q21 
has been narrowed to a 250 kb interval with TDT analysis (Hewett et al. 2002). 
 
19p13 PSORS6 
In a genome-wide study of 32 large German multiplex families with non-parametric 
linkage statistics, a novel psoriasis susceptibility locus at 19p13, PSORS6, (Zlr=3.50, 
P=0.0002) was reported. The authors also calculated linkage using parametric models 
by maximizing the LOD scores over multiple genetic models and obtained a LOD 
score of 2.38. When allowing heterogeneity under a recessive model, a LOD score of 
4.06 was reached. The genome-wide significance was assessed with simulations, and 
suggestive evidence of linkage was also seen at 6p21.3 (Zlr=3.1, P=0.001). Two loci 
on chromosomes 8q and 21q were also reported as possible susceptibility loci (Lee et 
al. 2000). 
 
1p PSORS7 
In a genome-wide screen of 284 affected sib-pairs of UK origin using non-parametric 
statistics, a novel susceptibility locus on 1p (NPL=3.6, P=0.00019), was reported 
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(PSORS7). However, also in this study the PSORS1 locus at 6p21.3 showed the most 
significant linkage, NPL=4.7 (P=2x10-6). In addition, suggestive evidence for linkage 
was detected at two novel loci, 2p and 14q, in families that were linked to the 
PSORS1 locus and at chromosome 7 in all families (Veal et al. 2001). 
 
 
Table 2. Genome-wide scans in psoriasis. 
Material: Studied loci: Linkage results: Reference: 
USA 
8 large families 
65/216 affected 
genome scan -17q25 PSORS2 (LOD 5.7) 
- dominant inheritance model 
 
Tomfohrde et al. (1994) 
Ireland 
1 large family unlinked 
to 17q 
 
6 large families 
(unlinked to 17q25) 
genome scan 
 
 
 
4q markers 
 
- 4q 
-dominant model 
 
 
- 4q35 PSORS3 (LOD 3.03, NPL 4.225, 
P=0.0026) 
Matthews et al. (1996) 
UK 
1: 254 individuals, 41 
families (66 ASPs) 
2: additional 27 families 
(40 ASPs) 
two-stage 
genome scan 
- 6p21.3 PSORS1 (LOD 6.5, P=5.8x10-7)  
- 2p  
- 8q  
- 20p  
 
Trembath et al. (1997) 
USA, Germany 
29 large and 86 nuclear 
families 
224 ASPs  
(182 independent) 
genome scan - 6p21.3 (LOD 3.52, P=2.9x10-5, NPL 2.54) 
- 16q  
- 20p 
- 17q  
 
Nair et al. (1997) 
Italy 
1 large family  
 
22 families 
 
genome scan 
 
 
6p, 17q and 1q 
markers 
-1cen-q21 (LOD 1.69) 
 
 
- 1q21 PSORS4 (LOD 3.75, NPL 4.1, 
P=0.0001)  
Capon et al. (1999) 
Sweden 
20 families 
 
153 ASPs 
 
 
genome scan 
 
 
3q markers 
-3q 
 
 
- 3q21 PSORS5 (LOD 3.36, recessive model, 
NPL 1.77), (NPL 2.77, P=0.003 in families 
from southwest Sweden) 
Enlund et al. (1999) 
 
 
Sweden 
134 ASPs 
 
 
genome scan - 6p21.3 (NPL 2.83, P=0.002) in families 
with no joint involvement 
- 3q21 (NPL 2.89, P=0.002) in families with 
no joint involvement 
-15 (NPL 2.96, P=0.0017) in families with 
joint involvement 
Samuelsson et al. (1999) 
Germany 
32 large families 
(162/357 affected) 
genome scan - 19p13 PSORS6 ( Zlr 3.5, P=0.0002) 
- 6p21.3 (Zlr 3.10, P=0.001) 
- 8q 
- 21q 
Lee et al. (2000) 
UK 
284 affected sib-pairs 
(222 independent 
sibships) 
 
genome scan - 6p21 (NPL 4.7, P=2x10-6) 
- 1p PSORS7 (NPL 3.6, P=0.00019)  
- 7 
- 2p 
- 14q 
Veal et al. (2001) 
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5. The PSORS1 locus in the MHC region 
 
Significant linkage to the PSORS1 locus at 6p21.3 has been reported in several 
studies of different populations (Nair et al. 1997; Trembath et al. 1997; Burden et al. 
1998; Samuelsson et al. 1999; Lee et al. 2000; Veal et al. 2001), and the locus fulfils 
the criteria for confirmed linkage (Lander and Kruglyak 1995). The contribution of 
the PSORS1 locus to the relative risk of developing familial psoriasis is calculated to 
be about 35-50% (Nair et al. 1997; Trembath et al. 1997; Burden et al. 1998). HLA 
association analyses also support the importance of the PSORS1 locus in psoriasis 
susceptibility, especially its tight association with the HLA-Cw*6 allele. The PSORS1 
locus is thus the major susceptibility locus for psoriasis. 
 
5.1. Refinement of PSORS1 
The PSORS1 locus has been further refined with association analyses of densely 
spaced markers across the MHC region to localize the PSORS1 gene. Balendran et al. 
(1999) genotyped 14 microsatellite markers to the susceptibility region. Using TDT 
analysis, the region was narrowed to a 285 kb interval (Balendran et al. 1999) (Fig. 2). 
In haplotype analysis, the most common haplotype among patients contained the 
HLA-B*5701 and HLA-Cw*0602 alleles (91 vs. 13 sibs, P<0.0001). In addition, a 
haplotype containing HLA-B*1302 and HLA-Cw*0602 was seen more frequently in 
patients than controls (23 vs. 3 sibs, P<0.001). A possible explanation for this is that 
HLA-Cw*0602 is the psoriasis susceptibility allele or that it is in strong linkage 
disequilibrium with the real disease allele. Another explanation is that the associated 
haplotypes define the HLA regions that contain alleles at a number of loci, all of 
which are required for disease predisposition (Balendran et al. 1999). 
 
Oka et al. (1999) genotyped 11 new microsatellites to a 1060 kb segment around the 
HLA-C gene. Three markers displayed significant deviation from Hardy-Weinberg’s 
equilibrium in psoriasis patients in the probability and heterozygote deficiency tests, 
and the susceptibility locus was narrowed down to a 111 kb region 89 kb telomeric to 
the HLA-C gene (Oka et al. 1999) (Fig. 2). 
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Figure 2. Map of the PSORS1 region displaying the positions of known genes. Arrows indicate the 
direction of transcription. The minimal refined regions in different studies are shown with solid black 
lines and broken lines illustrate the regions when interpreting the results more conservatively (Modified 
from Veal et al. 2002). 
 
Nair et al. (2000) genotyped 62 microsatellites across the MHC in 339 families and 
refined the locus to a 170 kb region centered 100 kb telomeric to HLA-C with short-
haplotype analysis. The authors next genotyped additional families (altogether 478) 
with 34 markers 1.2 Mb across the MHC and dissected the region further by 
recombinant ancestral haplotype analysis. They found two risk haplotypes, RH1 and 
RH2, which were separated only by a 2 kb interval. They concluded that RH1 was the 
most likely haplotype to carry the PSORS1 gene located 60 kb telomeric to HLA-C 
(Nair et al. 2000). The RH1 and RH2 haplotypes were otherwise continuous, but 
separated only by two microsatellites. This could be explained only by double 
recombinations between the two haplotypes, which would be extremely unlikely 
especially within MHC. The authors have therefore recently reanalyzed their data by 
sequencing the interval between RH1 and RH2 in carriers of different haplotype 
clusters. They found that the haplotype seems to be continuous across the interval 
between RH1 and RH2. The previous results could be explained by marker mutations 
in the intervening microsatellites. The susceptibility region for the PSORS1 gene was 
thus expanded to a 143 kb region telomeric to HLA-C (Nair et al. 2002) (Fig. 2). 
 
5.2. Candidate genes at PSORS1 
The complete sequence and the gene map of the MHC region have been published 
(Guillaudeux et al. 1998; Consortium 1999). Based on refinement studies, the region 
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of approximately 200 kb telomeric to HLA-C is most likely to contain the PSORS1 
gene (Fig. 2). The region contains at least four pseudogenes, NOB5, HCGIX-3, 
HCGII-2 and NOB4, and five genes HLA-C, TCF19 (SC1), OTF3 (POU5F1), HCR 
(Pg8) and CDSN (the S gene) (Zhou and Chaplin 1993; Krishnan et al. 1995; 
Guillaudeux et al. 1998; Consortium 1999). In addition, three poorly characterized 
unpublished genes, SEEK1, SPR1 and STG, have been mapped to the region (Fig. 2) 
(Oka et al. 1999). The region is interesting as a candidate locus for psoriasis because it 
contains several closely located genes, all of which are expressed in skin 
keratinocytes. 
 
Corneodesmosin (CDSN, earlier known as the S gene) is located 150 kb telomeric to 
HLA-C. The protein has been thoroughly studied and it is known to be expressed only 
in cornified squamous epithelia like skin epidermis. It is synthesized at the late stages 
of keratinocyte differentiation and is thought to play a major role in corneal layer 
cohesion. It is proteolysed during the maturation of the corneal layer of the epidermis, 
which is believed to be one of the major biochemical changes that leads to 
desquamation, making the gene a strong functional candidate for psoriasis (Zhou and 
Chaplin 1993; Haftek et al. 1997; Simon et al. 1997; Guerrin et al. 1998). 
 
In a Japanese population, the CDSN gene was found to be polymorphic with nine 
SNPs in the coding region, three of which were non-synonymous. None of the 
polymorphisms showed an association with psoriasis (Ishihara et al. 1996). In a case-
control study of a Caucasian population three non-synonymous SNPs, CDSN-619, 
-1240 and -1243 were analyzed for association with psoriasis. CDSN-1243*C was 
associated significantly with psoriasis; 65% of patients carried the allele but only 47% 
of controls (P=2x10-9). The HLA-Cw*6 allele showed, however, an even stronger 
association (36% vs. 10%, P=8x10-45). Both associations were stronger among type I 
psoriasis patients, and the CDSN-619*T and –1243*C alleles were in tight LD with 
HLA-Cw*6 (Tazi Ahnini et al. 1999). 
 
In a study by Allen et al. (1999), the same alleles, collectively called CDSN*5, 
showed a significant association with psoriasis in TDT analysis of 152 Caucasian trio 
families (P=3x10-6). The authors suggested that the association might be independent 
of the HLA-C association (Allen et al. 1999). Jenisch et al. (1999) reported similar 
 40
results when specifically different alleles of the CDSN gene were studied in a family 
material. They found seven alleles encoding six distinct protein forms of CDSN. One 
of them, CD2 containing CDSN*5, was associated significantly with psoriasis, again 
in strong LD with HLA-Cw*6 (Jenisch et al. 1999). 
 
Using immunohistochemistry and immunoelectron microscopy, the CDSN expression 
was found to be different between lesional psoriatic skin and normal or non-lesional 
skin. The results were specific for psoriasis and not seen in other studied 
inflammatory skin diseases. Whether the changes in CDSN expression in psoriasis 
were a fundamental effect contributing to the pathogenesis of the disease or merely a 
result of changes already occurring in the psoriatic skin remains to be determined 
(Allen et al. 2001). 
 
Of the other genes of the region, the OTF3 gene is a POU transcription factor and acts 
as a master regulator of pluripotency in the mammalian embryo (Niwa et al. 2000). 
The TCF19 (SC1) gene is preferentially expressed in the G1-S phase of the cell cycle 
and is considered to be a possible transactivating factor that could play a prominent 
role in the transcription of genes required for the later stages of cell cycle progression 
(Ku et al. 1991). Based on their broad and important functions in cell regulation, 
neither of the genes is an obvious candidate gene for psoriasis. In fact, sequencing of 
the coding regions of the genes failed to reveal any disease-specific variants (Nair et 
al. 2000). In a study of 67 Japanese patients and 103 controls, several polymorphisms 
in the TCF19 gene were discovered, however, none of them showed an association 
with psoriasis (Teraoka et al. 2000). In a Spanish population (95 patients and 104 
controls), the β-allele of the OTF3 gene showed a significant association with 
psoriasis but was clearly the major allele in both groups (85% vs. 60%, P<0.0003) and 
was shown to be in tight LD with the HLA-Cw*0602 allele (Gonzalez et al. 2000). 
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AIMS OF THE STUDY 
 
 
 
1. To characterize the structure of a novel candidate gene at the PSORS1 locus, 
HCR (Pg8), and screen the coding sequence for psoriasis-associated 
polymorphisms. 
 
2. To compare the associations of the different susceptibility alleles of the 
PSORS1 locus in different populations and subtypes of psoriasis to identify 
the PSORS1 gene. 
 
3. To study the expression of HCR mRNA and protein in lesional and non-
lesional psoriatic skin compared to normal skin. 
 
4. To search for minor susceptibility loci for psoriasis using a genome-wide scan 
in PSORS1 negative families. 
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MATERIALS AND METHODS 
1. Study subjects 
 
1.1. Finnish psoriasis families 
We recruited 142 psoriasis patients and 210 family members (100 families) from the 
central-eastern part of Finland (Kainuu province) during 1995-1997. In addition, 93 
population-matched control individuals were recruited. Of the Kainuu families, 100 
independent cases and 93 controls were analyzed in Study I. In 1999-2000, we 
expanded our sample collection and recruited additional families from all parts of 
Finland. In Study IV, large multiplex families (N=31) with three or more affected 
individuals per family, and in Study II, nuclear families (N=91) with a proband and 
parents (in some families also one parent affected) were analyzed. 
Inclusion criteria for probands were age of under 40 years and having chronic plaque 
psoriasis. Experienced dermatologists examined all patients and both patients and 
family members filled out a health questionnaire. All participants gave written 
informed consent and donated blood samples. The sample collection was approved by 
the Ethics Review Boards of all participating hospitals and the Department of Medical 
Genetics, University of Helsinki. 
 
1.2. Foreign psoriasis families 
For association analyses of the PSORS1 candidate alleles (Study II), DNA samples 
from psoriasis families of different ethnic origins were obtained. Most of the families 
were trios, British (N=175), Swedish (N=64), Italian (N=48) and Gujarati Indian 
(N=27), and 52 were multiplex Spanish families. In addition, separate case-control 
sample sets of 61 Gujarati Indian patients and 73 population–based controls and 83 
Japanese patients and 70 population-matched controls were analyzed. Clinical details 
of the patients are described in Table 1 of Study II. The collection of foreign samples 
was obtained with informed consent and was approved by the local Ethics Review 
Boards in each country. All samples were analyzed anonymously. 
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1.3. Guttate psoriasis and PPP patients 
For Study III, 134 British unrelated guttate psoriasis and 106 palmoplantar pustulosis 
patients were recruited. In addition, DNA from 309 population-matched controls was 
collected for the case-control study. A second PPP sample set (N=50) was collected 
from Sweden. Clinical details of the patients are described in Table 1 of Study III. 
Collection of foreign samples was obtained with informed consent and approved by 
local Ethics Review Boards.  
 
1.4. Skin biopsies 
Skin specimens were obtained from paired biopsies of the center of psoriatic plaques 
and non-lesional skin (I: N=6, II: N=16) and from healthy control skin from different 
parts of the body (I: N=3, II: N=7). For Study III, skin specimens were obtained from 
guttate psoriasis skin (N=6), PPP in various stages (N=20) and healthy control sole 
skin (N=7). All skin biopsies were fixed in formalin and embedded in paraffin.  
 
2. Reverse Transcriptase (RT)-PCR 
To amplify the HCR cDNA, total RNA was extracted from a primary keratinocyte 
cell line using RNeasy Mini Kit (Qiagen, Valencia, CA). RT-PCR was carried out 
with random hexamer primers using M-MLV reverse transcriptase (Promega, 
Madison, WI). The first-strand synthesis of cDNA was performed for 5 min at 70˚C 
followed by a 60 min incubation at 37˚C according to the manufacturer’s protocol (M-
MLV Reverse Transcriptase, Promega). 
 
3. PCR amplification and direct sequencing 
PCR assays were carried out in 20 µl volumes containing 50 ng of genomic DNA or 2 
µl of cDNA, 1x PCR buffer (10 mM Tris-HCl, 50 mM KCl, 0.1% triton X-100), 200 
µM dNTPs, 1.5 mM MgCl2, 0.6 µM primer mix and 0.6 U of DNA polymerase 
(DyNAzyme, Finnzymes, Espoo, Finland). The samples were denatured for 5 min at 
94οC, followed by 35-38 cycles each of 30 s at 94οC, 30 s at 55-68οC and 30-180 s at 
72οC. Purification of the PCR products was performed with a gel extraction or PCR 
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purification kit (Qiagen, Valencia, CA). Sequencing was performed by dye-terminator 
chemistry in both directions using the ABI 373A and ABI 377 sequencers. 
 
4. SSCP analysis 
SSCP gels were prepared in 50 ml volumes containing 10-12.5 ml of 2xMDE gel 
solution (FMC BioProducts, Rockland, ME), 6 ml of 5xTBE, 100 µl of 10% APS and 
40 µl of TEMED. The PCR-amplified samples were electrophoresed at 2-4 W for 17-
20 h, and the bands were visualized by silver staining. 
 
5. In situ hybridization 
The HCR probe was generated by RT-PCR amplification from the keratinocyte cell 
line using the primers ATTTAGGTGACACTATACattccctggagcctgagttt and TAATA 
CGACTCACTATAcctcctgctggatgaggc. T7 and Sp6 RNA polymerase promoter 
sequences were introduced at opposite ends of the 628 bp gene-specific product 
(lower case letters in primer sequences). In vitro transcribed antisense and sense RNA 
probes were labelled with 35S-marked UTP. In situ hybridization was performed at 
50°C overnight on formalin-fixed paraffin-embedded specimens using 4 x 104 cpm/ml 
of labelled probe. The slides were then washed under stringent conditions, including 
treatment of RNAse A. After autoradiography for 20-40 days, the photographic 
emulsion was developed and the slides were stained with haematoxylin and eosin for 
microscopy. A sense RNA probe was used as a negative control. 
 
6. Genotyping of SNPs 
The SNPs were genotyped using PCR amplification (see primer sequences from Study 
II) and altered restriction site recognizing enzymes for the Finnish, Swedish, Italian 
and Spanish samples. One primer was fluorescently labelled and the electrophoresis 
of the pooled digestion products was run on an ABI 377 sequencer. Allele calling was 
done using the Genotyper program (Applied Biosystems, Foster City, CA). PCR 
assays were carried out in 10 µl volumes containing 25 ng of genomic DNA, 1x PCR 
buffer (10 mM Tris-HCl, 50 mM KCl, 0.1% triton X-100), 200 µM dNTPs, 1.5 mM 
MgCl2, 0.5 µM primer mix, 1% DMSO and 0.3 U of DNA polymerase (DyNAzyme 
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II, Finnzymes, Espoo, Finland). Digestion reactions were performed overnight in 10 
µl reactions containing 5 µl of PCR product and 0.125-1 U of either BstUI 
(HCR*307), AvaII (HCR*325), Tsp509I (HCR*477), BsmFI (HCR*771), MslI 
(HCR*1723), HhaI (HCR*1911), MwoI (HCR*2327), MnlI (CDSN*619) or HphI 
(CDSN*1243), and the appropriate manufacturer's buffer (New England Biolabs, 
Beverly, MA). 
The HLA-Cw6 allele was genotyped using restriction enzymes MspA1I and DdeI or 
by SSP-PCR (Tonks et al. 1999). The digestion products were electrophoresed on 
agarose gels and photographed under UV illumination. 
The British, Japanese and Gujarati Indian samples were genotyped in the laboratory of 
Professor Richard Trembath using an allele-specific hybridization assay (Jeffreys et 
al. 2000). To validate the genotyping results of the two different methods, a control 
sample set was blindly genotyped with both assays in both laboratories. 
 
7. Production of antibodies 
Antisera against HCR protein were raised in rabbits by immunization with a synthetic 
18-mer peptide ERDVSSDRQEPGRRGRSW (amino acids 62-79). The peptide 
synthesis and antibody production were purchased from Sigma Genosys (Cambridge, 
UK). The antibodies were affinity-purified with the peptide bound to an epoxy-
activated sepharose column according to the manufacturer’s instructions (Pharmacia 
Biotech, Uppsala, Sweden).  
 
8. Western blotting 
To ascertain the specificity of the HCR antibodies, SDS-PAGE and Western blotting 
were carried out according to standard procedures. HCR cDNA was cloned into the 
pCMV5 vector and transiently expressed in COS-1 cells using the lipofection 
technique (Fugene, Roche, Indianapolis, IN). Affinity-purified HCR antibodies (1 
µg/ml) were used as primary and peroxidase-conjugated anti-rabbit IgG as secondary 
antibodies and detected with enhanced chemiluminiscence (Boehringer Mannheim, 
Mannheim, Germany).  
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9. Immunohistochemistry 
Immunostaining was performed on formalin-fixed paraffin-embedded specimens 
using the avidin-biotin-peroxidase complex technique for the HCR (II, III) (Vectastain 
ABC kit, Vector Laboratories Inc., Burlingame, CA) and Ki67 (II) antibodies 
(StreptABComplex/HRP Duet kit, Dako A/S, Glostrup, DK). Affinity-purified HCR 
antibodies were used at 4 µg/ml and anti-Ki67 was diluted to 1:200. Paraffin sections 
were pretreated with trypsin (10 mg/ml) (HCR) or antigen retrieval (Ki67). Ki67 
immunohistochemistry was performed on sections serial to those used for HCR. Both 
diaminobenzidine (DAB) and 3-amino-9-ethylcarbazole (AEC) were used as 
chromogenic substrates. The tissues were counterstained with haematoxylin. Controls 
were performed with preimmune serum. 
 
10. Genotyping of microsatellite markers 
Genome wide genotyping was done at the Finnish Genome Center using 377 
fluorescent polymorphic microsatellite markers from the Applied Biosystems Linkage 
Mapping Set MD-10. PCR assays were done in a 5 µl volume containing 20 ng of 
DNA and reagent concentrations and temperature profiles as recommended by the 
reagent manufacturer (Applied Biosystems). The electrophoreses were run using a 
MegaBace 1000 capillary instrument (Molecular Dynamics, Sunnyvale, CA) and 
allele calling was done using Genetic Profiler 1.1 (Molecular Dynamics) software.  
For fine-mapping markers, the PCR assays were done in a 10 µl volume. The 
electrophoreses were run using an ABI 377 sequencer and allele calling was done 
using Genotyper 2.0 (Applied Biosystems). 
 
11. Statistical analyses 
11.1. Linkage analysis 
Genome-wide linkage was analyzed using non-parametric multipoint linkage analysis 
(NPL) with GENEHUNTER 2.1 software (Kruglyak et al. 1996). 
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11.2. Haplotype association analysis 
Haplotyping was done within trios using an in-house computer program written by 
Petteri Sevon (unpublished). In the case of larger pedigrees, the program divided them 
into trios, randomly selecting one trio per pedigree in which at least one of the 
members was affected and genotyping information was available for all members 
(Spanish families in Study II) or finding the maximal number of independent trios 
with different chromosomes (IV). From each trio, four independent chromosomes 
were obtained. A chromosome was considered to be trait-associated if it occurred in 
any of the affected family members and to be a control if it occurred only in 
unaffected individuals. In case of ambiguities (missing genotypes, identical 
heterozygotic genotypes in all family members, or Mendel errors), the alleles were 
zeroed. 
Haplotype association analysis was performed using the Haplotype Pattern Mining 
(HPM) algorithm (Toivonen et al. 2000). HPM is a data mining-based method which 
searches for combinations of marker alleles that are more frequent in disease-
associated than in control chromosomes using a χ2 test. The haplotypes are allowed to 
contain gaps since missing data and genotyping errors, for instance, can disrupt the 
continuous haplotypes. The maximum number and length of the gaps can be 
determined. The haplotype patterns are ordered by their strength of association with 
the phenotype, and all haplotypes exceeding a given threshold level for χ2 are used for 
prediction of disease susceptibility gene location using a non-parametric model. The 
results obtained by considering marker frequencies can be contrasted against the null 
hypothesis that there is no gene effect using permutation tests. The chromosome status 
is permutated randomly, keeping the proportions of affected and control chromosomes 
constant. Marker-wise P values are approximated using permutations and the disease 
gene is predicted to be located near the marker with the smallest empirical P value 
(Toivonen et al. 2000). 
 
11.3. Transmission Disequilibrium Test (TDT) 
TDT was analyzed with GENEHUNTER 2.1 (Kruglyak et al. 1996). TDT evaluates 
the transmission of an associated marker allele from a heterozygous parent to an 
affected offspring compared with the transmission of the alternative marker allele. It 
tests directly for linkage between a disease and marker locus in the presence of 
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association and can thus distinguish between association due to linkage disquilibrium 
and association that arises only from population stratification (Spielman et al. 1993; 
Spielman and Ewens 1996). TDT in GENEHUNTER can analyze a maximum of 
four-marker haplotypes, and therefore for longer haplotypes, the TDT analyses were 
done manually. 
 
11.4. Other tests for allele association 
Allele associations for single SNPs or alleles were calculated counting only 
individuals who had genotyping data for that allele. The statistical significance 
between the case and control groups was calculated using χ2-test or Fisher’s exact test 
when the number of expected observations was less than five. The Bonferroni 
correction for multiple testing was carried out to reduce type I error (significance was 
accepted at the 5% level). Relative risk (RR) [RR=[a/(a+c)]/[b/(b+d)], where a is the 
number of patients with the risk allele; c the number of patients without the risk allele; 
b and d the equivalent values in the controls, respectively] or odds ratios (OR) 
[OR=f(aff)/(1-f(aff)):f(contr)/(1-f(contr))] with 95% confidence intervals (95% CI) were also 
calculated for each association. 
 
11.5. Linkage disequilibrium tests 
Linkage disequilibrium is the non-random association of alleles at linked loci. LD was 
calculated using different statistical measures: D, D´ and r2. The coefficient of linkage 
disequilibrium, D, is the difference between the observed haplotype frequency and the 
expected haplotype frequency under statistical independence (D=pAB-pApB). D 
depends on allele frequencies, and it was standardized to its theoretical maximum to 
get the normalized measure of LD, D´ (D´=D/Dmax, where Dmax=is the lesser of pApb 
or papB if D is positive or pApB or papb if D is negative). D´ depends strongly on 
sample size, and the square of the correlation coefficient, r2, was also calculated, 
r
2
=D2/(pApapBpb). r2 shows much less inflation in small samples than D´ but is 
affected by allele frequencies such as D (Jorde 2000; Ardlie et al. 2002; Weiss and 
Clark 2002). 
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RESULTS AND DISCUSSION 
1. Characterization of the HCR (Pg8) gene structure (I, II) 
The structure of the HCR gene was predicted using two different prediction programs, 
GENSCAN and FGENES. Primers were designed for the predicted exons and the 
coding sequence was verified with RT-PCR from keratinocyte RNA. The HCR gene 
consists of 18 exons and the coding sequence is 2349 bp encoding a protein of 782 
amino acids (GenBank AY29160). The sizes of the exons vary from 28 to 304 bp and 
the gene covers a 15.8 kb genomic region. The translation initiation codon is located 
in exon 2.  
 
2. Detection and screening of HCR polymorphisms (I, III) 
To detect possible sequence variations, all exons of the HCR gene were screened by 
direct sequencing using intronic primers in five Finnish psoriasis patients and one 
control. Two patients were HLA-Cw*6 positive and three negative to enrich for 
different variants. The genomic clone Y24c027 (GenBank AC004195) was used as a 
reference sequence. The gene was found to be highly polymorphic, with 18 SNPs in 
the coding region distributed in eight exons. Eleven SNPs caused an amino acid 
change and nine of them were non-conservative. Exons 4 and 10 were the most 
polymorphic, with five and four SNPs, respectively. All 18 SNPs with corresponding 
amino acid changes are shown in Table 3. 
 
In Study III, 14 PPP patients were sequenced to detect possible new PPP-specific 
polymorphism of the HCR gene. Two novel non-synonymous SNPs (HCR-326 G->A 
and HCR-2315 G->A) were found, but they were extremely rare, seen in one and two 
patients of the 106 patients, respectively. In addition, eight SNPs in the HCR gene not 
seen in the Kainuu population have since been published (O'Brien et al. 2001). Six of 
these SNPs seemed to be very rare also in the Swedish population and were seen in 
only one or two individuals of the 80-person study group (O'Brien et al. 2001). 
Because only six individuals were screened in our original polymorphism detection, 
rare polymorphisms may have gone unnoticed or simply did not exist in the studied 
population. However, a polymorphism not seen in any of the five sequenced psoriasis 
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patients is not likely to explain psoriasis in Finnish patients at the major psoriasis 
locus. 
 
2.1. Nomenclature of the HCR SNPs (I-IV) 
In Study I the detected HCR SNPs were numbered according to the verified cDNA 
sequence (GenBank AF216493). Two new exons, adding 135 bp to the 5’ end of the 
gene and 26 amino acids to the protein, were subsequently discovered (Study II). The 
SNP numbering was changed to correspond to the entire length of cDNA, base 
number one being the first base of the first methionine (GenBank AY029160). This 
may cause some confusion, but the base numbering starting from the first Met is 
commonly used for mutation reporting and was thus used in Studies II-IV. Both 
numberings for SNPs are shown in Table 3, but amino acids are numbered only 
according to the longer amino acid sequence. In Study I, two SNPs, HCR-307 (251) 
and HCR-325 (269), affect the translation and change the codon CGG (R, arginine) to 
TGG (W, tryptophan). Mistakenly, the amino acid designations were reversed 
throughout Study I (erratum published in Hum Mol Gen 2001, 10 (3) p. 301). 
 
3. Case-control association analysis of HCR SNPs (I) 
The 18 HCR SNPs were screened in 100 psoriasis patients and 93 population-matched 
controls from the Kainuu subisolate of Finland using parallel SSCP analysis and 
direct sequencing. Case-control studies are known to be very sensitive to population 
stratification, and by using a population isolate of homogenous background, the 
stratification could be minimized (Risch 2000; Cardon and Bell 2001). The allele and 
carrier frequencies of the SNPs are shown in Table 3. 
 
Two SNPs in exon 4 (HCR-307 and HCR-325) showed a significant association with 
psoriasis in the Kainuu population. Forty-two per cent of patients and 19% of controls 
possessed the HCR-307*T and –325*T alleles (P=0.00068, RR 2.2, 95% CI 1.7-2.6), 
which invariably occurred together. The two previously reported alleles of PSORS1, 
HLA-Cw*6 and CDSN*5, were also analyzed in the case-control sample set. The 
HLA-Cw*6 allele showed an even stronger association than the two HCR SNPs. 
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Thirty-seven per cent of patients and 9% of controls were carriers (P=3.1x10-6, RR 
4.3, 95% CI 3.1-5.0). CDSN*5 was the major allele in both groups, with 85-86% 
prevalence, and was not associated with psoriasis in the Kainuu population. 
 
4. Association and haplotype analysis of PSORS1 susceptibility alleles (II) 
To find out whether the HCR associations detected in the Kainuu population were 
associated with psoriasis in other populations as well, a large trio family material was 
analyzed. By genotyping families, the haplotype phase for the HCR SNPs could also 
be confirmed. Of the analyzed families, 164 were British, 91 Finnish, 62 Swedish, 47 
Italian, 26 Spanish and 29 Gujarati Indian trios. In addition to the seven HCR SNPs 
(HCR-307, -325, -477, -771, -1723, -1911, -2327), the HLA-Cw*6 and CDSN*5 
(CDSN-619 and –1243) alleles were genotyped in all 419 trios.  
 
When all families were pooled together (908 patient chromosomes, 772 control 
chromosomes) the HLA-Cw*6, HCR-307*T, HCR-325*T and HCR-1723*T alleles 
showed the strongest association with psoriasis in allele association analyses (P<10-10, 
OR>2). In haplotype analysis, a new HCR susceptibility allele was found. SNP alleles 
HCR-307*T, HCR-325*T, HCR-1723*T and HCR-2327*G were almost always 
inherited exclusively in the same chromosomes. The four SNPs were also the only 
non-synonymous ones of the studied HCR SNPs. All the other HCR SNP alleles of 
the HCR susceptibility haplotype (alleles bolded in Table 3) were clearly the major 
alleles in both patients and controls and were not haplotype-specific. The 
susceptibility allele, named HCR*WWCC, was seen in 35% of patient and 18% of 
control chromosomes (P=10-10, OR 2.5, 95% CI 1.9-3.3), also showing a significant 
association in TDT analysis (178 transmitted vs. 82 untransmitted chromosomes, 
P=10-11). 
 
However, the HLA-Cw*6 allele showed a similar or even stronger association in 
haplotype (P=10-11, OR 2.9, 95% CI 2.1-3.9) and TDT (157 transmitted vs. 48 
untransmitted, P=10-13) analyses. The CDSN*5 association remained somewhat lower 
(P=10-9, OR 2.0, 95% CI 1.6-2.5 in haplotype analysis and 275 transmitted vs. 180 
untransmitted, P=10-7 in TDT analysis) (Fig. 3). All three susceptibility alleles 
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seemed to be in strong linkage disequilibrium with each other, and the 95% CIs for 
the ORs were overlapping.  
The extended haplotype containing all three alleles was most significantly associated 
with psoriasis (OR 3.9, 95% CI 2.1-7.3). The P-value remained somewhat lower than 
for individual alleles (P=10-6). This was probably mainly due to the lower overall 
number of chromosomes because only chromosomes with genotyping data for all of 
the studied alleles of the haplotype were counted in each case.  
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Figure 3. Haplotype association results for PSORS1 susceptibility alleles in 908 psoriasis 
patient chromosomes compared with 772 control chromosomes. 
 
In LD analyses, HLA-Cw*6 and HCR*WWCC seemed to be in stronger LD 
(D´=0.73, r2=0.46 in patients) than HCR*WWCC and CDSN*5 (D´=0.41, r2=0.08 in 
patients). Based on the LD measurements and inspection of the haplotypes, little 
recombination occurred between the three genes, especially between HLA-C and 
HCR. The genes were probably included in the same haplotype block (Daly et al. 
2001; Patil et al. 2001; Reich et al. 2001), and even with this large sample size 
(almost 1700 chromosomes), the genes could not be separated with statistical 
confidence from each other.  
 
Two studies questioning the role of HCR as a psoriasis susceptibility gene have been 
published. In O’Brien et al. (2001), HCR polymorphisms were screened in 42 
Swedish patients and 38 controls. Two HCR SNPs, 1249*T and 1285*T, and the 
HLA-Cw*6 allele showed the most significant association with psoriasis and the 95% 
CI for ORs of the associated alleles overlapped. Based on stratification of the HCR 
alleles over HLA-Cw*6 and vice versa, the authors concluded that HCR is unlikely to 
P=10-11 
OR 2.9 (2.1-3.9) 
P=10-10 
OR 2.5 (1.9-3.3)
P=10-9 
OR 2.0 (1.6-2.5) 
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have an independent genetic effect on psoriasis (O'Brien et al. 2001). However, 
because of the small sample size and absence of chromosomal data, the study lacked 
the power to differentiate between HCR and HLA-C. Furthermore, the two 
associating HCR SNP alleles (1249*T and 1285*T) are included in the HCR*WWCC 
susceptibility haplotype, and the strong LD between this allele and HLA-Cw*6 has 
been confirmed in our large family-based study in different populations.  
 
Chia et al. (2001) suggested that HCR is unlikely to be causal for familial psoriasis 
because the HCR susceptibility SNPs (307*T, 325*T) were not seen in two of their 
haplotype clusters conferring risk to psoriasis (clusters 17 and 18). The disease 
association with cluster 17 shows, however, only a borderline P value (P=0.048) 
compared with the two clusters (21 and 25) that show the most significant association 
(P=10-4 and P=10-11, respectively) and carry the HLA-Cw*6, HCR 307*T and 325*T 
alleles (Nair et al. 2000; Chia et al. 2001). In addition, cluster 17 seems to be very 
rare, at least in the Finnish population. In 90 Finnish psoriasis trios, only three 
individuals (one affected) carried the cluster, and it is thus unlikely to carry the major 
disease variant (unpublished).  
 
5. PSORS1 allele associations in GP and PPP (III) 
The susceptibility alleles of the PSORS1 locus were genotyped in GP and PPP 
patients to find out whether the two clinical variants of psoriasis share the same 
genetic background with PV and whether they might be helpful in differentiating 
between the three genes. The HLA-C locus, 5 CDSN SNPs (+619, +1215, +1236, 
+1240, +1243), 10 HCR SNPs (+305, +307, +325, +492, +825, +1099, +1249, +1285, 
+1723, +2327) and two non-coding SNPs centromeric to HLA-C (SNP 7 and 9, Veal 
et al. 2002) were genotyped in 134 British GP, and 106 PPP patients and 309 
population-matched controls.  
 
5.1. GP shares genetic background with PV 
GP was strongly associated with HLA-Cw*6. Eighty-three per cent of patients and 
15% of controls carried the allele (OR 27.7, 95% CI 15.8-48.5, P=10-40). SNPs 7 and 
9 (OR 22.0-23.7, 95% CI 12.1-43.0, P=10-30-10-32) and all four HCR*WWCC allele-
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defining SNPs (OR 7.2-20.6, 95% CI 3.9-43.7, P=10-10-10-21) also showed a strong 
association with GP. The CDSN-1243*C allele was also more common in the GP 
group than in controls, but the association was weaker (OR 14.1, 95% CI 4.4-45.7, 
P=10-7). When examining the HCR*WWCC and CDSN*5 susceptibility alleles as a 
whole, which was possible because of the strong LD between the separate SNPs, all 
three PSORS1 susceptibility alleles seen with PV showed significant associations and 
their 95% CIs for ORs were overlapping. The HCR*WWCC association (OR 13.6, 
95% CI 7.7-24.1, P=10-23) was weaker than for HLA-Cw*6 (OR 27.7, 95% CI 15.8-
48.5, 10-40) but stronger than for CDSN*5 (OR 11.9, 95% CI 6.1-22.9, P=10-17) (Fig. 
4). The HCR*WWCC and CDSN*5 alleles were more common both in patients and 
controls than the HLA-Cw*6 allele, which could partly explain the weaker statistical 
significance measured as P values and ORs. All three susceptibility alleles tend to 
occur in the same individuals, consistent with a similar association with PSORS1 for 
both GP and PV. Thus, GP seems to share a genetic background with PV, and its 
PSORS1 association is even stronger. This may be influenced by the earlier onset of 
GP because early onset generally has a stronger association with PSORS1 than late 
onset (Henseler and Christophers 1985; Guedjonsson et al. 2002; Stuart et al. 2002). 
The type of the disease (PV vs. GP) is thus controlled by factors other than PSORS1. 
The second aim of the genotyping of the two subtypes was to differentiate the three 
genes, but the associations of the three alleles in GP were very similar to those seen in 
PV. Despite the stronger association with GP, the extended susceptibility haplotype 
remained intact.  
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Figure 4. Frequencies of PSORS1 susceptibility alleles in 134 British GP and 106  
PPP patients compared with 309 population-matched controls. 
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5.2. PPP is not associated with PSORS1 
PPP did not associate with HLA-Cw*6 or with any other HLA-C allele. Neither did 
the frequencies of any CDSN or HCR SNPs differ significantly between the PPP 
patients and controls (Fig. 4). To verify the negative finding in another population, the 
HCR*WWCC SNPs and the HLA-Cw*6 allele were also genotyped in 50 Swedish 
PPP patients. The allele frequencies were close to those seen in British PPP patients. 
The allele frequencies estimated from 124 Swedish control chromosomes (from Study 
II) were also similar to the frequencies seen in Swedish PPP patients.  
To exclude possible new PPP-specific variants in the HCR gene, the coding region 
was sequenced in 8 British and 6 Swedish patients. Two novel non-synonymous 
SNPs, HCR*326 G/A (in one British patient) and HCR*2315 G/A (in two British 
patients), were found. However, the SNPs seemed to be extremely rare, not being 
detected in any other patients when screening the 106 PPP patient cohort. 
The relationship between PPP and PV has been controversial. In this study, no 
association with any of the PSORS1 susceptibility alleles was detected. The lack of 
association could not be explained by the later onset of PPP compared with GP, 
because the frequencies of the PSORS1 risk alleles were in fact slightly lower among 
PPP patients with early age of onset (<40 years). PPP thus seems to be a genetic entity 
distinct from PV and GP, and its susceptibility is dependent on factors outside the 
PSORS1 interval. However, PV and PPP are likely to share common pathogenetic 
steps, as suggested by their concurrence in patients. The progression of the disorders 
probably involves regulatory genes other than those in the PSORS1 region.  
 
6. HCR mRNA is overexpressed in psoriatic skin (I) 
The HCR gene was shown by RT-PCR to be expressed at variable levels in all tissues 
tested (Human Multiple Tissue cDNA panel I, Clontech). The most abundant 
expression was seen in the heart, liver, skeletal muscle, kidney and pancreas, and 
weaker expression in the lung and placenta. Abundant expression was also seen in 
keratinocytes. In addition, HCR mRNA expression was studied by in situ 
hybridization of skin biopsies. HCR was strongly expressed in keratinocytes of 
psoriatic lesions, but normal looking skin of psoriasis patients and control skin were 
almost negative, suggesting upregulation of HCR in psoriatic keratinocytes. 
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7. Altered structure and expression of HCR protein in psoriasis (II, III)  
The predicted secondary structures of the wild-type and *WWCC susceptibility 
alleles of the HCR protein were analyzed with two programs that give the probability 
of coils, COIL and PAIRCOIL (Lupas et al. 1991; Berger et al. 1995). The probability 
of coil decreased dramatically at the sites of the four non-conservative amino acids of 
the HCR*WWCC allele compared with the wild-type form (Fig. 5). The altered 
secondary structure might affect the protein interactions or antigenic properties of the 
protein. In keratinocytes, this could lead to an altered response to a triggering antigen 
and initiate the disease process. However, the structural predictions must be viewed 
cautiously and assessed experimentally. 
 
 
Figure 5. (A) Genomic structure of the HCR gene showing the 18 exons (numbering below the boxes) 
and the location of the four non-synonymous SNPs of the HCR*WWCC allele. The introns are not 
drawn to scale. (B) Secondary structure predictions of the HCR protein showing the probability of coil. 
The wild-type allele is shown as a broken line and the psoriasis susceptibility allele as a solid line. The 
locations of the four amino acids of the HCR*WWCC allele are indicated by black arrowheads. 
 
HCR protein expression was studied with immunohistochemistry in skin biopsies 
using polyclonal peptide antibodies. In control and non-lesional skin, the basal 
keratinocytes were strongly and uniformly stained. In lesional psoriasis, expression 
was enhanced in basal keratinocytes at the tips of dermal papillae, whereas basal 
keratinocytes at rete ridges were mostly negative. This altered expression pattern was 
not seen in other inflammatory (eczema, lichen planus) or acanthotic (pityriasis rubra 
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pilaris) skin disorders resembling psoriasis. When parallel skin sections were stained 
with proliferation marker Ki67, the proliferating cells in psoriatic skin were most 
abundant at rete ridges, where HCR was only moderately expressed. HCR and Ki67 
showed thus an inverse staining pattern, which suggests that HCR might have a role 
in regulating keratinocyte proliferation. 
In skin sections from GP patients, HCR protein expression resembled that seen in PV. 
In PPP samples, much less HCR expression was detected, with only occasional 
staining of basal keratinocytes at the sides of PPP pustules. HCR protein expression is 
altered in the same way in both GP and PV. This supports the conclusion drawn from 
genetic analysis that GP shares genetic background with PV and suggests that the 
HCR protein might have a role in the disease process. Whether the altered expression 
is a primary event or is secondary to some other stimulus remains to be solved. PPP 
does, however, seem to have a different molecular genetic background. 
 
8. HCR gene orthologues in primates (unpublished) 
The coding region of the HCR gene and exon 2 of the HLA-C gene were sequenced 
from genomic DNA of the chimpanzee, pygmy chimpanzee, gorilla and orangutan to 
see whether the historic allelic structure of PSORS1 might be helpful in determining 
the age of the HCR*WWCC allele relative to the HLA-Cw*6 allele.  
As expected, the HCR gene was highly homologous with human HCR in all four 
apes, with 97-99% homology at both cDNA and amino acid sequence levels. None of 
the apes had any of the four SNP alleles defining the HCR*WWCC allele (307*T, 
325*T, 1723*T, 2327*G) or SNPs corresponding to the human HLA-Cw*6 allele. All 
of these alleles were minor alleles in humans (frequencies 23-35%) and thus expected 
to be newer and having emerged after the divergence of humans and great apes. 
Altogether 21 non-synonymous SNPs not seen in humans were found in one ape, and 
five of them in at least two apes. The amino acid changes did not cause radical 
differences in secondary structure predictions (unpublished). 
 
9. Defining the PSORS1 risk gene 
The three PSORS1 susceptibility alleles, HLA-Cw*6, HCR*WWCC and CDSN*5, 
are all coding variants and possibly directly cause disease pathogenesis. However, the 
 59
three alleles may show a significant association only because they are in LD with the 
actual, so far unidentified, disease allele. The PSORS1 region has been thoroughly 
studied and presumably all of the genes and their coding polymorphisms identified, 
but non-coding variants can also be causal if located for example on a regulatory 
region of a gene. 
 
In a recent study by Veal et al. (2002), a dense map of 59 SNPs across the PSORS1 
locus was genotyped in 171 trios. Haplotyping revealed five alternative major 
haplotype blocks at PSORS1. Two non-coding SNPs just a few kilobases centromeric 
to the HLA-C gene (SNP 7 and 9) showed the most significant association with 
psoriasis. In haplotype analysis, the associated alleles of SNPs 7 and 9 were unique to 
the overtransmitted chromosomes defining a 10 kb core risk haplotype. When 
studying LD between the known PSORS1 susceptibility alleles, LD was strongest in a 
block containing HLA-C and HCR but decreased markedly between this block and 
CDSN, as also seen in Study II. The SNPs 7 and 9 are non-coding and no known or 
predicted genes are located in their close proximity except HLA-C (distance 7 kb and 
4 kb, respectively) (Veal et al. 2002). However, all but one rare haplotype of the 
overtransmitted haplotypes also carry the HCR susceptibility allele. Moreover, the 
haplotype remains intact between SNPs 7 and 9 and the HCR allele in three different 
haplotype clusters comprising over half of all the overtransmitted chromosomes. In 
addition to the known coding variants of PSORS1, SNPs 7 and 9 are also possible 
candidates for PSORS1 disease variants. Because of the strong LD, especially in the 
centromeric part of PSORS1, none of the variants can, however, be prioritized based 
on current genetic analyses alone. 
 
Functional studies of the PSORS1 susceptibility alleles are sparse. Despite the HLA-
Cw*6 association being known for decades, the expression of HLA-C in psoriatic and 
normal skin is poorly characterized. The CDSN protein, by contrast, has been 
thoroughly studied. CDSN is a good functional candidate because of its role in the 
desquamation process of keratinocytes in the cornified layer, although the genetic 
association analyses support HLA-C or HCR instead. The CDSN protein expression 
has been shown to differ between lesional psoriatic skin and normal or non-lesional 
skin (Allen et al. 2001). HCR mRNA and protein expression was also different 
between lesional and non-lesional or control skin, and the HCR*WWCC allele was 
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predicted to adopt a different secondary structure than the wild-type allele (Study II). 
Whether the changes in CDSN or HCR expression in psoriasis are primary events in 
the pathogenesis of the disease or secondary to changes already occurring in psoriatic 
skin remain to be determined. The pathogenetic mechanisms of complex diseases are 
still largely unknown. Locus interaction is a possible mechanism and perhaps 
interaction between all of the PSORS1 susceptibility alleles is needed in the 
development of psoriasis. 
 
10. A minor locus for psoriasis on 18p in PSORS1 negative families (IV) 
Based on linkage and association analyses, the PSORS1 locus seems to explain one-
third to one-half of psoriasis. Other minor susceptibility loci are thus likely to exist. 
Several minor susceptibility loci have been detected in genome-wide scans, but the 
replication of these loci in different populations has been difficult. In addition to locus 
heterogeneity, the strong genetic effect of the PSORS1 locus might complicate the 
analyses in unselected family material.  
 
To find minor psoriasis susceptibility loci, only families showing no association with 
the PSORS1 locus were selected for a genome-wide scan. The PSORS1 association 
was excluded by genotyping two HCR SNPs (+325 and +1723) known to be in tight 
LD with the other SNPs of the HCR*WWCC haplotype as well as with the HLA-
Cw*6 and CDSN*5 alleles. Individuals having the 325*T and 1723*T alleles were 
defined as PSORS1 positive and the carriers of all the other allele combinations as 
negative. A PSORS1 negative family was defined as having more than two PSORS1 
negative patients and at least one transmission of psoriasis from parent to offspring 
without cotransmission of PSORS1. 
 
Altogether 31 families having at least three psoriasis patients per family were 
genotyped. Based on these results, nine PSORS1 negative families were selected for 
the genome-wide scan. The scan was performed at the Finnish Genome Center using 
377 fluorescently labelled microsatellite markers and the genome-wide linkage was 
analyzed using non-parametric (NPL) linkage analysis with GENEHUNTER 2.1 
(Kruglyak et al. 1996). 
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A total of five loci (11p, 12q, 15q, 18p, 22q) showing some evidence of linkage to 
psoriasis (NPL>1.7), and 3p for which a NPL score of 1.21 was observed 10 cM from 
the PSORS5 locus were selected for fine mapping with a 5 cM marker interval. The 
NPL scores remained essentially unchanged or decreased for all loci other than 18p. 
At 18p11, the NPL score increased sharply to 3.50 (P=0.0045), and after adding nine 
more markers, increasing the marker density to approximately 1 cM, a NPL score of 
3.58 (P=0.0038) was reached (Fig. 6). 
 
 
 
Figure 6. NPL curve of chromosome 18 with a peak of NPL 3.58 (P=0.0038) after fine mapping. 
Associated haplotypes are shown below the curve. The HPM haplotype is marked with a black box and 
the shared haplotype with a gray box. 
 
Haplotype sharing between the linked families gave additional support for the 18p 
locus. All patients in families showing the strongest evidence of linkage to 18p11 
shared the D18S471*2 allele. In addition, two of the families shared a three-marker 
haplotype (D18S458*2-D18S471*2-AFM238yg3*1) across the flanking markers. 
Association analysis with the HPM algorithm yielded evidence of an association for a 
 62
three-marker haplotype (D18S471*2-AFM238yg3*1-D18S967*4) that overlapped the 
haplotype shared between the linked families (Fig. 6). The haplotype was found in 
6/30 of patient but in 0/26 of control chromosomes (P=0.025). 
 
The significance of the 18p locus as a candidate locus for psoriasis is supported by 
two earlier reports. Nominal evidence of linkage and excess allele sharing at 18p has 
been reported in British psoriatic sib-pairs (NPL 1.97, P=0.025) (Veal et al. 2001). In 
addition, in a Swedish population, a susceptibility locus for an extreme atopic 
phenotype was also mapped to 18p (LOD 1.88, P<0.05) (Bradley et al. 2002). 
Psoriasis and atopic disease have been shown to share several other susceptibility loci, 
suggesting that genes at these loci might have general effects on dermal inflammation 
and immunity (Cookson et al. 2001). 
 
The PSORS1 locus has been shown to be associated with psoriasis, especially in 
patients with familial background. This was also the case in our material, with only 
three completely PSORS1 negative families being found. Because this was the first 
genome scan performed in only PSORS1 negative families, it will be interesting to 
see whether the locus appears in PSORS1 negative families in other populations. The 
markers showing evidence of haplotype association were unfortunately somewhat 
uninformative since the major allele was seen in the disease-associating haplotype. 
Additional, more informative markers will hopefully strengthen the haplotype 
association and refine the linked region. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
The major locus for psoriasis susceptibility, PSORS1, resides on chromosome 6p21.3 
in the MHC region. In this study, the structure of a novel candidate gene at PSORS1, 
HCR (Pg8), was defined. The HCR gene was found to be highly polymorphic and to 
carry a new susceptibility allele for psoriasis, HCR*WWCC. The two previously 
identified susceptibility alleles of PSORS1, HLA-Cw*6 and CDSN*5, showed, 
however, very similar disease association. The three candidate genes were in strong 
LD with each other, forming an extended risk haplotype similar in all populations 
studied, and separation of the genes was not possible with these sample sizes. 
 
The role of the PSORS1 locus in two clinical variants of psoriasis, guttate psoriasis 
and palmoplantar pustulosis, was also determined in this study. GP was associated 
with the PSORS1 locus even more strongly than psoriasis vulgaris, giving further 
support for the notion that GP and PV share the same genetic background. The 
stronger association with PSORS1, however, did not help in differentiating the 
PSORS1 genes. The relationship between psoriasis and PPP has long been 
controversial. In this first systematic study of the PSORS1 susceptibility alleles in 
PPP patients, the PSORS1 association could be excluded, which speaks strongly for 
different etiologies or molecular mechanisms for PPP as compared with PV or GP. 
 
The PSORS1 locus has been studied intensively by several research groups from all 
over the world during the last few years. Recent studies on the PSORS1 locus have 
clearly shown that defining the PSORS1 risk gene will require an extremely large 
sample size. The studied 1700 chromosomes in this study were insufficient to detect 
ample recombinations to separate the genes of the PSORS1 locus from each other. 
Within the last year, the first steps towards of a large collaborative study of the 
PSORS1 locus with many participating PSORS1 research groups have been taken. 
This study will offer a comprehensive analysis of the PSORS1 locus, and it will be 
interesting to see whether the genes can be separated with genetic methods. 
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One hypothesis is that all three PSORS1 genes act together in the disease process. In 
addition to the HLA-C, HCR and CDSN genes, several other genes expressed in skin 
keratinocytes, such as SPR1, SEEK1 and STG, are located at the PSORS1 locus. 
While the polymorphisms of these genes do not show as strong an association with 
psoriasis, they may also be involved if the genes of PSORS1 form a functional 
complex of genes affecting keratinocyte function. The genes of the minor 
susceptibility loci might also interact with the PSORS1 genes or have a function 
elswhere in the pathogenetic chain. In this study, a new minor locus for psoriasis 18p 
was found which is believed to explain psoriasis risk in some patients without the 
PSORS1 gene defect.  
 
Functional studies are eventually needed to determine the actual disease-causing 
effect of the PSORS1 gene/genes. Thus far, functional studies on the genes of 
PSORS1 have been very limited. In this study, functional support for HCR as a 
potential psoriasis gene was gained. In addition to disease association, the 
HCR*WWCC allele was predicted to have an altered secondary structure compared 
with the wild-type allele. This could lead to an altered antigenic response. The 
expression of the HCR mRNA and protein also differed between lesional psoriatic 
skin and non-lesional psoriatic and normal control skin. HCR is thus a tempting 
candidate gene for psoriasis. However, at the moment, the function of the protein can 
only be hypothesized, with more studies needed to determine the role of the HCR 
protein in the pathogenesis of psoriasis.  
 
Psoriasis is a complex disease and patients are likely to have different genetic 
variations behind disease susceptibility. In the future, when the molecular genetic 
background of psoriasis in each patient can be determined, treatments can be more 
individually targeted. As the pathogenetic mechanisms of the disease become known, 
novel therapies will likely emerge.  
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